Page last updated: 2024-12-05

idebenone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Idebenone is a synthetic benzoquinone derivative that is structurally similar to Coenzyme Q10. It has been studied for its potential therapeutic effects in various conditions, including Alzheimer's disease, Parkinson's disease, and age-related macular degeneration. Idebenone is thought to act as an antioxidant, protecting cells from damage caused by free radicals. It also has been shown to improve mitochondrial function and enhance energy production in cells. Idebenone is synthesized through a multi-step process that involves the coupling of a quinone derivative with an alkyl chain. It is available as a prescription drug in some countries, and it is also being studied for its potential use in other conditions, such as stroke and traumatic brain injury.'

Cross-References

ID SourceID
PubMed CID3686
CHEMBL ID252556
CHEBI ID31687
SCHEMBL ID28320
MeSH IDM0111395

Synonyms (112)

Synonym
HMS3393O06
AB00639997-06
mnesis
avan
qsa-10
a-68500
cv-2619
idebenone ,
sovrima
catena
snt-mc17
cerestabon
brn 2001459
2,5-cyclohexadiene-1,4-dione, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-
idebenonum [latin]
2,5-cyclohexadiene-1,4-dione, 5,6-dimethoxy-2-(10-hydroxydecyl)-3-methyl-
2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
idebenona [spanish]
6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone
cv 2619
idebenone [inn:jan]
MLS001424002
smr000466364
MLS000759487
NCGC00160514-01
58186-27-9
idebenone (jan/usan/inn)
raxone (tn)
D01750
2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
HMS2089D08
HMS2051O06
AC-4337
nsc-759228
CHEMBL252556
oristar hdu
chebi:31687 ,
hydroxydecyl ubiquinone
MLS001032035
STK801942
5,6-dimethoxy-2-(10-hydroxydecyl)-3-methyl-1,4-benzoquinone
AKOS005622577
dtxsid0040678 ,
tox21_111864
dtxcid8020678
cas-58186-27-9
pharmakon1600-01505755
nsc759228
2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-1,4-benzoquinone
I0848
CCG-100846
idebenona
nsc 759228
unii-hb6pn45w4j
idebenonum
hb6pn45w4j ,
FT-0617205
BBL025842
NCGC00160514-03
S2605
idebenone [who-dd]
idebenone [ema epar]
hydroxydecyl ubiquinone [inci]
idebenone [mart.]
idebenone [jan]
idebenone [inn]
idebenone [usan]
idebenone [mi]
FR114
AB00639997-04
raxone
HY-N0303
2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylbenzo-1,4-quinone
2,3-dimethoxy-6-(10-hydroxydecyl)-5-methyl-1,4benzoquinone
2,3-dimethoxy-6-(10-hydroxydecyl)-5-methyl-1,4-benzoquinone
2,3-dimethoxy-6-(10-hydroxydecyl)-5-methylbenzoquinone
NC00096
SCHEMBL28320
tox21_111864_1
NCGC00160514-02
KS-5193
mfcd00274552
2,3-dimethoxy-5-methyl-6-(10'-hydroxydecyl)-1,4-benzoquinone
MLS006011882
2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione
STR09227
1189907-75-2
AB00639997_08
AB00639997_07
idebenone, analytical standard
SR-01000759378-6
sr-01000759378
SR-01000759378-5
SR-01000759378-4
idebenone, >=98% (hplc)
HMS3656K22
bdbm50505498
SBI-0207024.P001
HMS3713A10
SW219495-1
Q4197874
BCP09116
BRD-K37516142-001-01-4
SB19130
HMS3884B12
SY051193
2-(10-hydroxydecyl)-6-methoxy-3-methyl-5-(trideuteriomethoxy)cyclohexa-2,5-diene-1,4-dione
H10427
EN300-7359600
BI164565
idebenone- bio-x
Z2216898922

Research Excerpts

Overview

Idebenone is a coenzyme Q10 synthetic quinone analog and an antioxidant. It has been used in humans to treat diverse diseases. The mechanisms underlying the neuroprotection in cerebral ischemia and reperfusion (I/R) remain elusive.

ExcerptReferenceRelevance
"Idebenone is a coenzyme Q10 synthetic quinone analog and an antioxidant that has been used in humans to treat diverse diseases in which mitochondrial function is impaired."( Improved Mitochondrial Metabolism and Reduced Inflammation Following Attenuation of Murine Lupus With Coenzyme Q10 Analog Idebenone.
Blanco, LP; Carmona-Rivera, C; Hoffmann, V; Kaplan, MJ; Lightfoot, YL; Pedersen, HL; Seto, N; Wang, X; Yu, ZX; Yuen, PST, 2020
)
1.49
"Idebenone is a synthetic analogue of coenzyme Q10."( Esculetin and idebenone ameliorate galactose-induced cataract in a rat model.
Al-Hamid, HA; El-Boghdady, NA; Omar, NN; Sadik, NAH, 2020
)
1.64
"Idebenone is a synthetic quinone that on reduction in cells can bypass mitochondrial Complex I defects by donating electrons to Complex III. "( Idebenone Has Distinct Effects on Mitochondrial Respiration in Cortical Astrocytes Compared to Cortical Neurons Due to Differential NQO1 Activity.
Ge, SX; Jaber, SM; Milstein, JL; Polster, BM; VanRyzin, JW; Waddell, J, 2020
)
3.44
"Idebenone is a well-appreciated mitochondrial protectant while the mechanisms underlying the neuroprotection in cerebral ischemia and reperfusion (I/R) remain elusive. "( Idebenone attenuates cerebral inflammatory injury in ischemia and reperfusion via dampening NLRP3 inflammasome activity.
Gong, Z; He, L; Li, X; Pan, J; Peng, J; Peng, Y; Shen, Q; Wang, H, 2020
)
3.44
"Idebenone (IDB) is a synthetic analog of Coenzyme Q10 (CoQ10) carrying antioxidizing property."( Idebenone protects mitochondrial function against amyloid beta toxicity in primary cultured cortical neurons.
He, Y; Jia, K; Li, L; Lin, Y; Sui, S; Wang, H; Wang, Q, 2020
)
2.72
"Idebenone is an analog of the well-known antioxidant compound coenzyme Q10 (CoQ10)."( Idebenone Ameliorates Rotenone-Induced Parkinson's Disease in Rats Through Decreasing Lipid Peroxidation.
Avcı, B; Bilge, SS; Günaydın, C; Güvenç, T; Kuruca, N; Yavuz, CK, 2021
)
2.79
"Idebenone is a well described drug that was initially developed against dementia. "( Idebenone: When an antioxidant is not an antioxidant.
Eri, R; Gueven, N; Ravishankar, P; Rybalka, E, 2021
)
3.51
"Idebenone (IDB) is a yellow crystalline powder that is used in the treatment of chronic cerebrovascular diseases."( Effect of idebenone on bone marrow mesenchymal stem cells in vitro.
Chen, H; Li, T; Sun, X; Tang, S; Tao, Z; Zhang, J; Zhang, N; Zhou, X, 2018
)
1.6
"Idebenone is a hydrophilic short-chain coenzyme (Co) Q analogue, which has been used as a potential bypass of defective complex I in both Leber Hereditary Optic Neuropathy and OPA1-dependent Dominant Optic Atrophy. "( The idebenone metabolite QS10 restores electron transfer in complex I and coenzyme Q defects.
Acosta Lopez, MJ; Argenton, F; Bernardi, P; Carelli, V; Carini, M; Da Ros, T; Galber, C; Giorgio, V; Petronilli, V; Prato, M; Salviati, L; Schiavone, M, 2018
)
2.48
"Idebenone is an approved drug and could be considered for other indications such as type 2 diabetes and fatty liver disease, in which insulin resistance occurs."( Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition.
Allen, S; Bettaieb, A; Cortopassi, G; Hui, CK; Tomilov, A, 2018
)
2.64
"Idebenone is a potent antioxidant which has already been evaluated in several clinical trials in FRDA, with reports of symptomatic benefit but inconclusive objective results."( Patient-reported outcomes in Friedreich's ataxia after withdrawal from idebenone.
Boesch, S; Brunt, E; Cook, A; Giunti, P; Heck, S; Klockgether, T; Schöls, L; Schulz, A, 2019
)
1.47
"Idebenone is a ubiquinone analog with antioxidant, and ATP replenishment effects."( Neuroprotective effects of idebenone against pilocarpine-induced seizures: modulation of antioxidant status, DNA damage and Na(+), K (+)-ATPase activity in rat hippocampus.
Ahmed, MA, 2014
)
1.42
"Idebenone (IDE) is a lipophilic benzoquinone electron carrier synthetic analogue of coenzyme Q10, which behaves as an antioxidant and free radical scavenging molecule. "( Antioxidant activity of idebenone-loaded neutral and cationic solid-lipid nanoparticles.
Crasci', L; Leonardi, A; Panico, A; Pignatello, R, 2015
)
2.17
"Idebenone is a short-chain quinone analogue with a potent free-radical scavenger action."( Monitoring cardiac function during idebenone therapy in Friedreich's ataxia.
Bahaa, F; Giovanni, DS; Majid, AF; Valeria, P, 2015
)
1.42
"Idebenone is a high permeable drug with very slight water solubility that affects the dissolution rate in the biological fluids, causing an irregular and limited in vivo absorption after oral administration. "( Innovative oral spray-dried Idebenone systems to improve patient compliance.
Aquino, RP; Carbone, C; Chillemi, R; Lauro, MR; Puglisi, G; Ruozi, B; Sansone, F; Sciuto, S, 2016
)
2.17
"Idebenone is a synthetic analog of coenzyme Q; both share a quinone moiety but idebenone has a shorter lipophilic tail ending with a hydroxyl group. "( Both idebenone and idebenol are localized near the lipid-water interface of the membrane and increase its fluidity.
Corbalán-García, S; de Godos, AM; Gómez-Fernández, JC; Gómez-Murcia, V; Torrecillas, A, 2016
)
2.39
"Idebenone is a rapidly absorbed, safe and well-tolerated drug and is currently the only clinically proven treatment option for Leber's hereditary optic neuropathy (LHON) patients. "( Idebenone for Leber's hereditary optic neuropathy.
Gueven, N, 2016
)
3.32
"Idebenone is a synthetic short chain benzoquinone that acts as an electron carrier in the mitochondrial electron transport chain facilitating the production of adenosine triphosphate."( New Micellar Electrokinetic Chromatographic Method for Analyzing Idebenone in Pediatric Formulations.
Buontempo, F; Contin, M; Dobrecky, C; García Becerra, C; Lucangioli, S; Tripodi, V, 2017
)
1.41
"Idebenone is a synthetic analogue of ubiquinone that may be beneficial in the treatment of Friedreich's ataxia. "( Pharmacokinetics and metabolism of idebenone in healthy male subjects.
Bodmer, M; Dreier, M; Drewe, J; Kutz, KW; Vankan, P, 2009
)
2.07
"Idebenone is a synthetic short chain benzoquinone that acts as an electron carrier in the mitochondrial electron transport chain, thereby, facilitating the production of ATP. "( Pharmacokinetic evaluation of idebenone.
Becker, C; Bray-French, K; Drewe, J, 2010
)
2.09
"Idebenone is a coenzyme Q10 analog and an antioxidant that has been used clinically to treat Friedreich Ataxia. "( Idebenone induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells.
Pham, L; Tai, KK; Truong, DD, 2011
)
3.25
"Idebenone (IDB) is a synthetic antioxidant and analog of coenzyme Q10. "( Nanostructured lipid carriers improve skin permeation and chemical stability of idebenone.
Ge, ZQ; Li, B, 2012
)
2.05
"Idebenone is a benzoquinone analog that is used in the treatment of several neurological disorders including Friedreich's ataxia. "( Determination of idebenone in plasma by HPLC with post-column fluorescence derivatization using 2-cyanoacetamide.
Kubo, H; Nohara, Y; Suzuki, J; Yamazaki, Y, 2012
)
2.16
"Idebenone (IDE) is an antioxidant compound, structurally related to coenzyme Q10. "( Chemical and technological delivery systems for idebenone: a review of literature production.
Carbone, C; Musumeci, T; Pignatello, R; Puglisi, G, 2012
)
2.08
"Idebenone is a synthetic analogue of coenzyme Q10 with antioxidant properties. "( Protective properties of idebenone in noise-induced hearing loss in the guinea pig.
Ferraresi, A; Fetoni, AR; Mordente, A; Navarra, P; Paludetti, G; Sergi, B; Troiani, D, 2006
)
2.08
"Idebenone is a stable analog of the antioxidant coenzyme Q(10)."( A comparison of the relative antioxidant potency of L-ergothioneine and idebenone.
Canning, MT; Damaghi, N; Dong, KK; Kibitel, J; Smiles, KA; Yarosh, DB, 2007
)
1.29
"Idebenone is a lower molecular weight analog of coenzyme Q(10) (a potent antioxidant)."( Determination of the antioxidative capacity of an antioxidant complex and idebenone: an in vitro rapid and sensitive method.
Cordoba-Diaz, M; Hui, X; Maibach, HI; Wa, C; Zhai, H, 2008
)
1.3
"Idebenone is a benzoquinone compound which has been investigated in elderly patients with dementia. "( Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders.
Benefield, P; Gillis, JC; McTavish, D, 1994
)
3.17
"Idebenone is a very effective substrate for succinate:Q reductase and ubiquinol:cytochrome c reductase, but it is clearly a poor substrate for NADH:Q reductase (complex I)."( The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria.
Benelli, B; Carelli, V; Esposti, MD; Ghelli, A; Linnane, AW; McLennan, H; Ngo, A, 1996
)
1.25
"Idebenone is a quinone analog that is applied in the treatment of several neurological disorders including Friedreich ataxia and mitochondrial encephalomyopathies. "( Monitoring of idebenone treatment in patients with Friedreich's ataxia by high-pressure liquid chromatography with electrochemical detection.
Aracil, A; Artuch, R; Colomé, C; Pineda, M; Vilaseca, MA, 2002
)
2.12

Effects

Idebenone has been investigated as a drug therapy for Leber's hereditary optic neuropathy (LHON), a rare genetic mitochondrial disease that causes rapid and progressive bilateral vision loss. The drug has shown a positive effect on left ventricular heart mass.

ExcerptReferenceRelevance
"Idebenone has recently been approved in Europe for treating LHON."( Visual function in chronic Leber's hereditary optic neuropathy during idebenone treatment initiated 5 to 50 years after onset.
Kircher, K; Pemp, B; Reitner, A, 2019
)
1.47
"Idebenone has recently been investigated as a drug therapy for Leber's hereditary optic neuropathy (LHON), a rare genetic mitochondrial disease that causes rapid and progressive bilateral vision loss. "( The ying and yang of idebenone: Not too little, not too much - cell death in NQO1 deficient cells and the mouse retina.
Beirne, K; Brancale, A; Heard, C; Newland, B; Rozanowska, M; Varricchio, C; Votruba, M, 2020
)
2.32
"Idebenone (IDB) has demonstrated the potential to treat mitochondrial and neurodegenerative diseases, including Alzheimer's disease (AD). "( Effectiveness of idebenone nanorod formulations in the treatment of Alzheimer's disease.
Fu, Q; Guo, M; He, Z; Huang, Y; Li, M; Liu, P; Ma, M; Zhu, X, 2021
)
2.4
"Idebenone (IDE) has been proposed for the treatment of neurodegenerative diseases involving mitochondria dysfunctions. "( In Vitro Antioxidant Activity of Idebenone Derivative-Loaded Solid Lipid Nanoparticles.
Crascì, L; Modica, MN; Montenegro, L; Panico, AM; Puglisi, G; Romeo, G; Salerno, L, 2017
)
2.18
"Idebenone has been proposed as a means of bypassing defective complex I activity and a free radical scavenger to prevent oxidative damage. "( Is there treatment for Leber hereditary optic neuropathy?
Newman, NJ; Peragallo, JH, 2015
)
1.86
"Idebenone has been investigated as a treatment in several neurological disorders like Friedreich's ataxia, Leber's hereditary optic neuropathy, mitochondrial encephalomyopathies and senile dementia."( New Micellar Electrokinetic Chromatographic Method for Analyzing Idebenone in Pediatric Formulations.
Buontempo, F; Contin, M; Dobrecky, C; García Becerra, C; Lucangioli, S; Tripodi, V, 2017
)
1.41
"Idebenone has shown a positive effect on left ventricular heart mass but no research on clinical relevance of this change has been done."( Antioxidants and other pharmacological treatments for Friedreich ataxia.
Fahey, M; Kearney, M; Orrell, RW; Pandolfo, M, 2009
)
1.07
"Idebenone has been used as therapy for Friedreich ataxia for more than a decade. "( Intermediate-dose idebenone and quality of life in Friedreich ataxia.
Brandsema, JF; Hartley, J; Stephens, D; Yoon, G, 2010
)
2.14
"Idebenone has shown a positive effect on left ventricular heart mass but the clinical relevance of this change was not assessed in the included study."( Antioxidants and other pharmacological treatments for Friedreich ataxia.
Fahey, M; Kearney, M; Orrell, RW; Pandolfo, M, 2012
)
1.1

Actions

ExcerptReferenceRelevance
"Idebenone is a lower molecular weight analog of coenzyme Q(10) (a potent antioxidant)."( Determination of the antioxidative capacity of an antioxidant complex and idebenone: an in vitro rapid and sensitive method.
Cordoba-Diaz, M; Hui, X; Maibach, HI; Wa, C; Zhai, H, 2008
)
1.3

Treatment

Idebenone treatment significantly corrected cardiac diastolic dysfunction and prevented mortality from cardiac pump failure induced by dobutamine stress testing in vivo. The drug was able to reduce the levels of oxidative stress markers, such as H.

ExcerptReferenceRelevance
"The Idebenone treatment was able to reduce the levels of oxidative stress markers, such as H"( Protection of dystrophic muscle cells using Idebenone correlates with the interplay between calcium, oxidative stress and inflammation.
Hermes, TA; Macedo, AB; Mâncio, RD; Minatel, E; Mizobuti, DS; Moraes, FDSR; Moraes, LHR; Valduga, AH, 2023
)
1.65
"Idebenone treatment effectively stabilized the atherosclerotic plaques."( Idebenone Protects against Atherosclerosis in Apolipoprotein E-Deficient Mice Via Activation of the SIRT3-SOD2-mtROS Pathway.
Geng, H; Jiang, W; Lin, P; Liu, F; Lv, X; Ma, J; Yan, C, 2021
)
2.79
"Idebenone is now a treatment option for LHON."( A teenager with acute bilateral visual loss.
Jørstad, ØK; Kerty, E; Ødegaard, EM, 2018
)
1.2
"Idebenone treatment significantly corrected cardiac diastolic dysfunction and prevented mortality from cardiac pump failure induced by dobutamine stress testing in vivo, significantly reduced cardiac inflammation and fibrosis, and significantly improved voluntary running performance in mdx mice."( Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance.
Barzaghi, P; Buyse, GM; Courdier-Fruh, I; D'hooge, J; Erb, M; Herijgers, P; Jara, A; Meier, T; Mertens, L; Van Den Bergh, A; Van der Mieren, G; Verbeken, E, 2009
)
1.32
"Idebenone treatment resulted in a trend (p=0.067) to increase peak systolic radial strain in the left ventricular inferolateral wall, the region of the heart that is earliest and most severely affected in DMD."( Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial.
Buyse, GM; Ceulemans, B; de Groot, IJ; Goemans, N; Meier, T; Mertens, L; Schara, U; Thijs, D; van den Hauwe, M, 2011
)
2.53
"Idebenone treatment at early stages of the disease seems to reduce the progression of cerebellar manifestations."( Friedreich's ataxia: idebenone treatment in early stage patients.
Aracil, A; Artuch, R; Colomé, C; Mas, A; Monrós, E; Pineda, M; Rissech, M, 2002
)
1.35
"Idebenone treatment did not affect APP and Apo E alterations in this condition."( Changes in amyloid precursor protein and apolipoprotein E immunoreactivity following ischemic brain injury in rat with long-term survival: influence of idebenone treatment.
Barcikowska, M; Debicki, G; Januszewski, S; Pluta, R; Ryba, M, 1997
)
1.22
"Idebenone treated rats showed no increase in TBAR contents, and a marked attenuation of changes in the other indices."( Changes in oxidative stress in the rat brain during post-cardiac arrest reperfusion, and the effect of treatment with the free radical scavenger idebenone.
Chrapusta, SJ; Debicki, GS; Gordon-Krajcer, W; Grieb, P; Januszewski, S; Ryba, MS,
)
1.05
"Idebenone treatment (30 mg/kg per day, p.o.) markedly decreased the LPO to the level of the controls."( Effects of idebenone on lipid peroxidation and hemolysis in erythrocytes of stroke-prone spontaneously hypertensive rats.
Nagaoka, A; Shibota, M; Suno, M, 1989
)
1.39
"Oral treatment with idebenone 300 mg tid was started in seven patients 5 to 51 years after LHON onset. "( Visual function in chronic Leber's hereditary optic neuropathy during idebenone treatment initiated 5 to 50 years after onset.
Kircher, K; Pemp, B; Reitner, A, 2019
)
1.07
"Treatment with idebenone was safe and well tolerated with adverse event rates were similar in both groups."( Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial.
Bernert, G; Buyse, GM; Cuisset, JM; D'Angelo, MG; Finkel, RS; Goemans, N; McDonald, CM; Meier, T; Rummey, C; Schara, U; Straathof, CSM; Voit, T, 2015
)
1.14
"Treatment with idebenone improved tritan color vision compared with placebo (P = 0.008 at week 24); a similar trend was seen for protan."( Effects of idebenone on color vision in patients with leber hereditary optic neuropathy.
Al-Tamami, J; Büchner, B; Dimitriadis, K; Heck, S; Klopstock, T; Leinonen, M; Meier, T; Rudolph, G; Rummey, C; Seidensticker, F, 2013
)
1.12
"Treatment with idebenone can protect from loss of color vision, particularly in patients who are at imminent risk of further vision loss."( Effects of idebenone on color vision in patients with leber hereditary optic neuropathy.
Al-Tamami, J; Büchner, B; Dimitriadis, K; Heck, S; Klopstock, T; Leinonen, M; Meier, T; Rudolph, G; Rummey, C; Seidensticker, F, 2013
)
1.12
"Treatment with idebenone was found effective on memory, attention, and orientation and in slowing down the natural progressive worsening of the disease."( Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type.
Bergamasco, B; La Commare, P; Scarzella, L,
)
1.91
"Treatment with idebenone (10-1000 nM), a potent antioxidant in mitochondria, protected the hippocampal neurons against the Abeta1-40(10 microM)-induced neurotoxicity."( Idebenone protects hippocampal neurons against amyloid beta-peptide-induced neurotoxicity in rat primary cultures.
Hayako, H; Hirai, K; Kato, K; Miyamoto, M, 1998
)
2.08
"Pretreatment with idebenone (10-100 mg/kg, p.o.) for 3 or 10 days delayed the onset of ischemic seizure (acute stroke) and prolonged survival time in SHRSP roughly in a dose-dependent manner."( Effects of idebenone on neurological deficits, local cerebral blood flow, and energy metabolism in rats with experimental cerebral ischemia.
Kakihana, M; Nagaoka, A; Shibota, M; Suno, M, 1989
)
0.99
"Pretreatment with idebenone (10 mg/kg, i.p.) inhibited the decrease in ACh and the increase in choline in the forebrain regions."( Effects of idebenone on the levels of acetylcholine, choline, free fatty acids, and energy metabolites in the brains of rats with cerebral ischemia.
Kakihana, M; Nagaoka, A; Yamazaki, N, 1989
)
0.99

Toxicity

ExcerptReferenceRelevance
" The toxic potencies of glutamate, quisqualate, and homocysteate were inversely proportional to the concentration of cystine in the medium, suggesting that they competitively inhibit cystine uptake."( Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake.
Coyle, JT; Murphy, TH; Schnaar, RL, 1990
)
0.28
" Safety parameters were adverse events, vital signs, ECG and clinical laboratory parameters."( Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study.
Gutzmann, H; Hadler, D, 1998
)
0.58
"We studied the type, number, and frequency of adverse events, and pharmacokinetic parameters including maximum drug concentration, time to maximum drug concentration, area under the curve, and half-life."( Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia.
Di Prospero, NA; Fischbeck, KH; Penzak, SR; Ravina, B; Sumner, CJ; Taylor, JP, 2007
)
0.59
" All adverse events were mild, and pharmacokinetic parameters including maximum drug concentration, time to maximum drug concentration, and half-life did not differ significantly across age cohorts."( Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia.
Di Prospero, NA; Fischbeck, KH; Penzak, SR; Ravina, B; Sumner, CJ; Taylor, JP, 2007
)
0.59
"The aim of this study was to investigate the toxic impacts of titanium dioxide nanoparticles (TiO₂-NPs) on rat kidneys and the possible prophylactic role of either quercetin or idebenone."( Potential impact of quercetin and idebenone against immuno- inflammatory and oxidative renal damage induced in rats by titanium dioxide nanoparticles toxicity.
Abdel Baky, NA; Al-Rasheed, NM; Faddah, LM; Mohamed, AM; Mohammad, RA, 2013
)
0.86
" Importantly, the treatment of IDB alone demonstrated an indiscernible side effect on the measured mitochondrial function, PKA/CREB signaling and neuronal viability."( Idebenone protects mitochondrial function against amyloid beta toxicity in primary cultured cortical neurons.
He, Y; Jia, K; Li, L; Lin, Y; Sui, S; Wang, H; Wang, Q, 2020
)
2

Pharmacokinetics

This review summarizes the pharmacology, pharmacokinetic and clinical efficacy/safety data of idebenone and its metabolites. It provides an update of the clinical trials completed and in progress.

ExcerptReferenceRelevance
" Blood and urine samples were collected for pharmacokinetic analysis of CV-2619 and its two major metabolites."( An early phase I study to determine the tolerance, safety and pharmacokinetics of idebenone following multiple oral doses.
Barkworth, MF; Dyde, CJ; Johnson, KI; Schnelle, K, 1985
)
0.49
" Plasma concentrations of idebenone and its main metabolites were determined and the pharmacokinetic parameters of idebenone after single and repeated doses were estimated."( Plasma concentrations and pharmacokinetics of idebenone and its metabolites following single and repeated doses in young patients with mitochondrial encephalomyopathy.
Autret, E; Blin, O; Desnuelle, C; Durand, A; Joubert, M; Legout, V; Pinsard, N; Pisano, P; Serratrice, G, 1996
)
0.85
"We studied the type, number, and frequency of adverse events, and pharmacokinetic parameters including maximum drug concentration, time to maximum drug concentration, area under the curve, and half-life."( Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia.
Di Prospero, NA; Fischbeck, KH; Penzak, SR; Ravina, B; Sumner, CJ; Taylor, JP, 2007
)
0.59
" Variability in absorption of the drug was observed, but drug half-life was relatively consistent across dose levels."( Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia.
Di Prospero, NA; Fischbeck, KH; Penzak, SR; Ravina, B; Sumner, CJ; Taylor, JP, 2007
)
0.59
" Since in previous pharmacokinetic trials only lower doses were studied, it was the aim of this study to evaluate the pharmacokinetics of idebenone in higher doses of up to 2,250 mg/day."( Pharmacokinetics and metabolism of idebenone in healthy male subjects.
Bodmer, M; Dreier, M; Drewe, J; Kutz, KW; Vankan, P, 2009
)
0.83
" Non-compartmental standard pharmacokinetic methods were used."( Pharmacokinetic properties and metabolism of idebenone.
Drewe, J; Kutz, K; Vankan, P, 2009
)
0.61
"This review summarizes the pharmacology, pharmacokinetic and clinical efficacy/safety data of idebenone and its metabolites and provides an update of the clinical trials completed and in progress."( Pharmacokinetic evaluation of idebenone.
Becker, C; Bray-French, K; Drewe, J, 2010
)
0.87

Compound-Compound Interactions

Butyphthalide combined with idebenone can effectively reduce serum inflammatory factor level of VD patients, regulate vascular endothelial functions, relieve dementia degree, and improve cognitive function and daily activity ability.

ExcerptReferenceRelevance
"This study investigates the effect of insulin combined with idebenone on blood-brain barrier (BBB) permeability in experimental streptozotocin-induced diabetic rats as well as the underlying mechanisms."( Effects of insulin combined with idebenone on blood-brain barrier permeability in diabetic rats.
Liu, LB; Sun, YN; Wang, P; Xue, YX, 2015
)
0.94
"To determinate the clinical effect of butyphthalide combined with idebenone in the treatment of vascular dementia (VD) and the influence on inflammatory cytokines and vascular endothelial functions."( Effects of Butyphthalide Combined with Idebenone on Inflammatory Cytokines and Vascular Endothelial Functions of Patients with Vascular Dementia.
Gao, TC; Hu, Y; Kang, LJ; Li, P; Qi, FX; Zhang, X, 2020
)
1.06
" Idebenone was given to the control group, and butyphthalide combined with idebenone was given to the observation group for 12 weeks."( Effects of Butyphthalide Combined with Idebenone on Inflammatory Cytokines and Vascular Endothelial Functions of Patients with Vascular Dementia.
Gao, TC; Hu, Y; Kang, LJ; Li, P; Qi, FX; Zhang, X, 2020
)
1.74
"Butyphthalide combined with idebenone can effectively reduce serum inflammatory factor level of VD patients, regulate vascular endothelial functions, relieve dementia degree, and improve cognitive function and daily activity ability."( Effects of Butyphthalide Combined with Idebenone on Inflammatory Cytokines and Vascular Endothelial Functions of Patients with Vascular Dementia.
Gao, TC; Hu, Y; Kang, LJ; Li, P; Qi, FX; Zhang, X, 2020
)
1.12

Bioavailability

A new self-microemulsifying drug delivery system (SMEDDS) was developed to increase the dissolution rate, solubility, and bioavailability of a poorly water soluble drug. The improved action of idebenone-loaded liposomes is probably due to the greater drug bioavailability at the cellular level.

ExcerptReferenceRelevance
"A new self-microemulsifying drug delivery system (SMEDDS) was developed to increase the dissolution rate, solubility, and, ultimately, bioavailability of a poorly water soluble drug, idebenone."( Preparation and in vitro evaluation of self-microemulsifying drug delivery systems containing idebenone.
Chi, SC; Hahn, M; Kim, HJ; Park, ES; Yoon, KA, 2000
)
0.72
" The improved action of idebenone-loaded liposomes is probably due to the greater drug bioavailability at the cellular level."( Tolerability and improved protective action of idebenone-loaded pegylated liposomes on ethanol-induced injury in primary cortical astrocytes.
Cardile, V; Fresta, M; Iannone, M; Paolino, D; Puglisi, G; Renis, M; Rotiroti, D, 2004
)
0.89
" Complementary administration of antioxidants with high bioavailability should be considered if oxidative stress is present."( Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects.
Area, E; Dimauro, S; Hirano, M; López, LC; Naini, A; Quinzii, CM; Rahman, S; Salviati, L; Schuelke, M, 2010
)
0.36
" We have probably wasted too much time on agents like antioxidant vitamins instead of focusing on more disease specific, target-directed, highly bioavailable antioxidants."( Antioxidant therapy: current status and future prospects.
Firuzi, O; Miri, R; Saso, L; Tavakkoli, M, 2011
)
0.37
" Our results suggest that these SLN could be regarded as a promising drug delivery system to improve IDE bioavailability and antioxidant activity."( Idebenone loaded solid lipid nanoparticles interact with biomembrane models: calorimetric evidence.
Castelli, F; Montenegro, L; Ottimo, S; Puglisi, G; Sarpietro, MG, 2012
)
1.82
"Cyclodextrin inclusion complexes, liposomes, microemulsions, prodrugs, polymeric and lipid nanoparticles have been explored to achieve different goals, such as topical administration, brain targeting or increasing the bioavailability of this highly lipophilic drug."( Chemical and technological delivery systems for idebenone: a review of literature production.
Carbone, C; Musumeci, T; Pignatello, R; Puglisi, G, 2012
)
0.63
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The objective of this study is to fabricate IDB nanorods (IDBNRs) to improve oral bioavailability and increase concentrations in the brain in order to enhance therapeutic effects of IDB in the treatment of AD."( Effectiveness of idebenone nanorod formulations in the treatment of Alzheimer's disease.
Fu, Q; Guo, M; He, Z; Huang, Y; Li, M; Liu, P; Ma, M; Zhu, X, 2021
)
0.96

Dosage Studied

Noben (idebenone) was administered in dosage 120 mg during 6 months to 35 patients, aged from 60 to 86 years. Patients had dementia, Alzheimer's type and mixed type, and with memory disturbances which did not reach the level of dementia.

ExcerptRelevanceReference
" All patients received noben as a main drug in dosage 5 mg/kg daily during 3 months."( [The use of noben for correction of mitochondrial disorders in Friedrich's disease].
Ershova, MV; Illarioshkin, SN; Sukhorukov, VS, 2007
)
0.34
"Noben (idebenone) was administered in dosage 120 mg during 6 months to 35 patients, aged from 60 to 86 years, with dementia, Alzheimer's type and mixed type, and with memory disturbances which did not reach the level of dementia."( [Noben (idebenone) in the treatment of dementia and memory impairment without dementia].
Meleshkov, MN; Voronkova, KV, 2008
)
1.24
"We performed a 6-month, randomized placebo-controlled, double-blind, dose-response pilot trial to assess the safety and efficacy of erythropoietin in increasing frataxin levels."( Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial.
Caldarazzo, S; Cappellini, MD; Di Bella, D; Duca, L; Fancellu, R; Lauria, G; Mariotti, C; Nanetti, L; Plumari, M; Solari, A; Taroni, F, 2012
)
0.38
" Consistent with the reported dosing and observed effects in LHON patients, we describe that in mice, idebenone penetrated into the eye at concentrations equivalent to those which protected RGC-5 cells from complex I dysfunction in vitro."( Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy.
Anklin, C; Erb, M; Gueven, N; Heitz, FD; Pernet, V; Robay, D, 2012
)
2.04
" Of the 7 drugs, idebenone dose-dependently bound Shc protein in the 50-100 nM range, and induced insulin sensitivity and cytoprotection in this same 100 nM range that clinically dosed idebenone reaches in human plasma."( Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition.
Allen, S; Bettaieb, A; Cortopassi, G; Hui, CK; Tomilov, A, 2018
)
2.26
"The large variations observed among the different individuals involved in this study should be considered for optimization of individual dosage regimens."( Plasma idebenone monitoring in Friedreich's ataxia patients during a long-term follow-up.
Artuch, R; Cesar, S; Colom, H; Cuadras, D; Darling, A; Del Mar O'Callaghan, M; Genovès, J; Latre, C; Martorell, L; Montero, R; Paredes-Fuentes, AJ; Pineda, M; Sarquella-Brugada, G, 2021
)
1.08
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
ferroptosis inhibitorAny substance that inhibits the process of ferroptosis (a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides) in organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
primary alcoholA primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.
1,4-benzoquinonesAny member of the class of benzoquinones that is 1,4-benzoquinone or its C-substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (55)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency14.12540.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency25.11890.044717.8581100.0000AID485341
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency4.45630.140911.194039.8107AID2451
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID485281
LuciferasePhotinus pyralis (common eastern firefly)Potency37.93300.007215.758889.3584AID588342
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency26.83253.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency17.49350.006038.004119,952.5996AID1159521; AID1159523
TDP1 proteinHomo sapiens (human)Potency5.34440.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency23.71010.000714.592883.7951AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency28.18380.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency19.04400.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743053; AID743054; AID743063
thioredoxin glutathione reductaseSchistosoma mansoniPotency39.81070.100022.9075100.0000AID485364
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency23.71010.000657.913322,387.1992AID1259377; AID1259378
progesterone receptorHomo sapiens (human)Potency33.49150.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.48970.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency32.47970.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency19.62770.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency4.91290.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency20.41590.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency29.74550.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743078; AID743079; AID743091
GVesicular stomatitis virusPotency7.76190.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency3.89020.00108.379861.1304AID1645840
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency50.11870.707936.904389.1251AID504333
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency26.60110.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency21.64760.001019.414170.9645AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency26.83250.023723.228263.5986AID743223
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency13.53450.035520.977089.1251AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency29.84930.001723.839378.1014AID743083
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency3.790219.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency23.91450.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency49.19400.039147.5451146.8240AID1224845
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency31.67040.000323.4451159.6830AID743065; AID743067
huntingtin isoform 2Homo sapiens (human)Potency35.48130.000618.41981,122.0200AID1688
mitogen-activated protein kinase 1Homo sapiens (human)Potency39.81070.039816.784239.8107AID1454
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency16.81590.00798.23321,122.0200AID2546; AID2551
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency18.10560.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency27.00500.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency33.49150.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency7.76190.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency7.76190.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency18.83360.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency33.49150.001551.739315,848.9004AID1259244
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency22.38720.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency7.76190.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency13.33320.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency13.33320.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency7.76190.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)7.00000.00011.753610.0000AID625251
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)10.00000.00011.68479.3200AID1614268
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)3.00000.00002.015110.0000AID625249
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)5.00000.00002.800510.0000AID625248
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)0.80000.00002.398310.0000AID625247
NAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)IC50 (µMol)15.40000.50003.848110.0000AID1526043
NAD-dependent protein deacetylase Schistosoma mansoniIC50 (µMol)1.90001.90001.90001.9000AID1526021
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (282)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
rDNA heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
autophagyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitotic nuclear membrane reassemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of exit from mitosisNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of autophagyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of peptidyl-threonine phosphorylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
substantia nigra developmentNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
myelination in peripheral nervous systemNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
subtelomeric heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of myelinationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to oxidative stressNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
peptidyl-lysine deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
epigenetic regulation of gene expressionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of phosphorylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of DNA bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
post-translational protein modificationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular lipid catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NLRP3 inflammasome complex assemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
innate immune responseNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of fatty acid biosynthetic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of meiotic nuclear divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of striated muscle tissue developmentNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of DNA-templated transcriptionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cell divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
meiotic cell cycleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of cell cycleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
response to redox stateNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of cell divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of attachment of spindle microtubules to kinetochoreNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to caloric restrictionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of oligodendrocyte progenitor proliferationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to hypoxiaNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to epinephrine stimulusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
tubulin deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of execution phase of apoptosisNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of oocyte maturationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of NLRP3 inflammasome complex assemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of satellite cell differentiationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (103)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromatin bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
zinc ion bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone acetyltransferase bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone deacetylase bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
tubulin deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
ubiquitin bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
DNA-binding transcription factor bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein demyristoylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein depalmitoylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
transcription factor bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (68)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
chromosome, telomeric regionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromosomeNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitochondrionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
centrosomeNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
centrioleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
microtubuleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
plasma membraneNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
growth coneNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
midbodyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
paranodal junctionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
paranode region of axonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
perikaryonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
myelin sheathNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
lateral loopNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
Schmidt-Lanterman incisureNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
juxtaparanode region of axonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
perinuclear region of cytoplasmNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitotic spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
meiotic spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
glial cell projectionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
heterochromatinNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromatin silencing complexNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (205)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID754345Effect on total ATP level in CoQ10-deficient human GM17932 cells after 48 hrs by bioluminescence assay2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID502264Cytoprotective activity against diethyl maleate-induced cell death in human CEM cells assessed as cell viability at 2.5 uM treated 18 hrs before diethyl maleate challenge measured after 4 hrs by trypan blue assay2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Synthesis and characterization of mitoQ and idebenone analogues as mediators of oxygen consumption in mitochondria.
AID738672Inhibition of NADH oxidase in bovine heart submitochondrial particles at 5 uM after 5 mins by spectrophotometric analysis relative to untreated control2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection.
AID1700564Suppression of rotenone-induced ATP depletion in human HepG2 cells assessed as rescue of ATP level at 5 uM incubated for 2 hrs in presence of complex III inhibitor antimycin by Celltiter-Glo assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Discovery of Novel 2-Aniline-1,4-naphthoquinones as Potential New Drug Treatment for Leber's Hereditary Optic Neuropathy (LHON).
AID1637920Cytoprotection against rotenone-induced mitochondrial dysfunction in human HepG2 cells assessed as acute ATP rescue at 10 uM co-treated with rotenone for 1 hr by luciferase-based assay relative to control2019MedChemComm, Mar-01, Volume: 10, Issue:3
Amide linked redox-active naphthoquinones for the treatment of mitochondrial dysfunction.
AID312787Inhibition of Fe2+-induced lipid peroxidation in rat brain homogenate2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Synthesis and evaluation of 2'-hydroxyethyl trans-apovincaminate derivatives as antioxidant and cognitive enhancer agents.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID703750Cytoprotection in diethyl maleate-treated human CCRF-CEM cells 2.5 uM incubated for 17 hrs before diethyl maleate challenge by trypan blue dye exclusion method (Rvb = 18 +/- 10%)2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Analysis of the structural and mechanistic factors in antioxidants that preserve mitochondrial function and confer cytoprotection.
AID729228Cell cycle arrest in human mitochondrial gene-knockout HL60 cells assessed as accumulation at G2 phase at 30 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 18 %)2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Anti-leukemic activity of ubiquinone-based compounds targeting trans-plasma membrane electron transport.
AID1700557Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 25 uM incubated for 24 hrs by Celltiter-blue assay relative to control2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Discovery of Novel 2-Aniline-1,4-naphthoquinones as Potential New Drug Treatment for Leber's Hereditary Optic Neuropathy (LHON).
AID738410Inhibition of NADH-ubiquinone oxidoreductase activity in bovine heart submitochondrial particles using coenzyme Q1 as substrate after 5 mins by spectrophotometric analysis relative to untreated control2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID738411Inhibition of NADH-ubiquinone oxidoreductase activity in bovine heart submitochondrial particles using coenzyme Q1 as substrate after 5 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID738673Inhibition of NADH oxidase in bovine heart submitochondrial particles at 1 uM after 5 mins by spectrophotometric analysis relative to untreated control2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection.
AID754327Cytoprotective activity against diethyl maleate-induced oxidative stress in Alzheimer's disease patient AG06849 cells assessed as cell viability at 0.5 uM preincubated for 15 hrs prior to diethyl maleate-challenge measured after 6 hrs by hemocytometer-bas2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID754341Effect on total ATP level in CoQ10-deficient human GM17932 cells at 25 uM after 48 hrs by bioluminescence assay relative to control2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID754319Cytoprotective activity against diethyl maleate-induced oxidative stress in Parkinson's disease patient GM15010 cells assessed as cell viability at 2.5 uM preincubated for 15 hrs prior to diethyl maleate-challenge measured after 6 hrs by hemocytometer-bas2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID703749Cytoprotection in diethyl maleate-treated human Friedreich's ataxia lymphocytes incubated for 17 hrs before diethyl maleate challenge by trypan blue dye exclusion method2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Analysis of the structural and mechanistic factors in antioxidants that preserve mitochondrial function and confer cytoprotection.
AID729235Antiproliferative activity against human mitochondrial gene-knockout HL60 cells after 48 hrs by MTT assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Anti-leukemic activity of ubiquinone-based compounds targeting trans-plasma membrane electron transport.
AID539470Solubility of the compound in water2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID1700569Cytotoxicity against C57BL/6J mouse RGC cells at 20 uM incubated for 24 hrs by Hoechst 33342 staining based counting method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Discovery of Novel 2-Aniline-1,4-naphthoquinones as Potential New Drug Treatment for Leber's Hereditary Optic Neuropathy (LHON).
AID1700567Suppression of rotenone-induced ATP depletion in human HepG2 cells assessed as increase in rescue of ATP level at 0.1 to 1 uM incubated for 2 hrs by Celltiter-Glo assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Discovery of Novel 2-Aniline-1,4-naphthoquinones as Potential New Drug Treatment for Leber's Hereditary Optic Neuropathy (LHON).
AID754318Cytoprotective activity against diethyl maleate-induced oxidative stress in human CCRF-CEM cells assessed as cell viability at 2.5 uM preincubated for 15 hrs prior to diethyl maleate-challenge measured after 6 hrs by hemocytometer-based assay2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID760295Cytoprotective activity against diethyl maleate-induced loss of mitochondrial membrane integrity in human Friedreich's ataxia lymphocytes at 100 nM incubated overnight prior to diethyl maleate-treatment measured after 140 mins by TMRM staining-based FACS 2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
An optimized pyrimidinol multifunctional radical quencher.
AID738412Inhibition of NADH oxidase in bovine heart submitochondrial particles at 10 uM after 5 mins by spectrophotometric analysis relative to untreated control2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection.
AID1808090Stability in human gut microbes assessed as half life by LC-MS analysis2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1091120Antifeedant activity against Coptotermes formosanus placed on 1 % wt/wt compound treated filter paper assessed as filter paper consumption measured 21 days post compound exposure (Rvb = 42.4 +/- 4.3 mg)2008Journal of agricultural and food chemistry, Jun-11, Volume: 56, Issue:11
Activity of 1,4-benzoquinones against formosan subterranean termites (Coptotermes formosanus).
AID642427Growth inhibition of human FRDA primary patient fibroblasts after 48 hrs by calcein-AM-based cell viability assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID729229Cell cycle arrest in human mitochondrial gene-knockout HL60 cells assessed as accumulation at S phase at 30 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 24 %)2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Anti-leukemic activity of ubiquinone-based compounds targeting trans-plasma membrane electron transport.
AID729231Cell cycle arrest in human mitochondrial gene-knockout HL60 cells assessed as accumulation at sub G1 phase at 30 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 3 %)2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Anti-leukemic activity of ubiquinone-based compounds targeting trans-plasma membrane electron transport.
AID703751Cytoprotection in diethyl maleate-treated human CCRF-CEM cells 0.5 uM incubated for 17 hrs before diethyl maleate challenge by trypan blue dye exclusion method (Rvb = 18 +/- 10%)2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Analysis of the structural and mechanistic factors in antioxidants that preserve mitochondrial function and confer cytoprotection.
AID754344Effect on total ATP level in CoQ10-deficient human GM17932 cells at 5 uM after 48 hrs by bioluminescence assay relative to control2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID738399Cytoprotective effect in human CEM cells assessed as reduction of diethyl maleate-induced oxidative stress measured cell viability at 1 uM incubated for 17 hrs prior to diethyl maleate challenge measured after 6 hrs by trypan blue exclusion assay relative2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection.
AID1700558Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability at 25 uM incubated for 24 hrs by Celltiter-blue assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Discovery of Novel 2-Aniline-1,4-naphthoquinones as Potential New Drug Treatment for Leber's Hereditary Optic Neuropathy (LHON).
AID760287Effect on total ATP level in human Friedreich's ataxia lymphocytes at 5 uM after 48 hrs by bioluminescence assay relative to control2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
An optimized pyrimidinol multifunctional radical quencher.
AID754322Cytoprotective activity against diethyl maleate-induced oxidative stress in Friedreich's ataxia disease patient GM15850 cells assessed as cell viability at 2.5 uM preincubated for 15 hrs prior to diethyl maleate-challenge measured after 6 hrs by hemocytom2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID1808091Drug metabolism in mini gut model assessed as metabolite formation by LC-MS/MS analysis2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach.
AID729239Cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 30 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 28 %)2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Anti-leukemic activity of ubiquinone-based compounds targeting trans-plasma membrane electron transport.
AID1700568Cytoprotection against rotenone-induced C57BL/6J mouse retinal ganglion cells loss assessed as cell survival at 10 uM incubated for 24 hrs by Hoechst 33342 staining based counting method (Rvb = 41%)2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Discovery of Novel 2-Aniline-1,4-naphthoquinones as Potential New Drug Treatment for Leber's Hereditary Optic Neuropathy (LHON).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1700554Suppression of rotenone-induced ATP depletion in human HepG2 cells assessed as rescue of ATP level at 5 uM incubated for 2 hrs by Celltiter-Glo assay relative to control2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Discovery of Novel 2-Aniline-1,4-naphthoquinones as Potential New Drug Treatment for Leber's Hereditary Optic Neuropathy (LHON).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1614268Inhibition of human 5-LOX using arachidonic acid as substrate measured after 10 mins by ELISA2019Bioorganic & medicinal chemistry, 02-15, Volume: 27, Issue:4
Design, synthesis and identification of novel coumaperine derivatives for inhibition of human 5-LOX: Antioxidant, pseudoperoxidase and docking studies.
AID738408Effect on cellular respiration in rat RGC5 cells assessed as increase in mitochondrial oxygen consumption at 10 uM after 1.5 hrs by fluorescence assay relative to vehicle-treated control2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection.
AID1091095Termiticidal activity against Coptotermes formosanus placed on 1 % wt/wt compound treated filter paper assessed as termite mortality measured 11 days post compound exposure2008Journal of agricultural and food chemistry, Jun-11, Volume: 56, Issue:11
Activity of 1,4-benzoquinones against formosan subterranean termites (Coptotermes formosanus).
AID642429Therapeutic index, ratio of LC50 to GI50 for human FRDA primary patient fibroblasts2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID760294Cytoprotective activity against diethyl maleate-induced loss of mitochondrial membrane integrity in human Friedreich's ataxia lymphocytes at 250 nM incubated overnight prior to diethyl maleate-treatment measured after 140 mins by TMRM staining-based FACS 2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
An optimized pyrimidinol multifunctional radical quencher.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID754343Effect on total ATP level in Friedreich's ataxia disease patient GM15850 cells after 48 hrs by bioluminescence assay2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID760284Decrease in total ATP level in CoQ10-deficient human GM17932 cells after 48 hrs by bioluminescence assay2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
An optimized pyrimidinol multifunctional radical quencher.
AID1432453Antioxidant activity in FRDA patient derived lymphocytes assessed as inhibition of DEM-mediated lipid peroxidation at 0.1 to 2.5 uM pretreated for 16 hrs followed by DEM addition measured after 120 mins by C11-BODIPY581/591 probe-based FACS analysis2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Influence of substituent heteroatoms on the cytoprotective properties of pyrimidinol antioxidants.
AID642426Cytoprotective activity against BSO-induced human FRDA primary patient fibroblasts compound pretreated 12 hrs prior to BSO-induction measured after 48 hrs by calcein-AM-based cell viability assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID736839Antioxidant activity in mouse HT22 cells assessed as prevention of glutamate-induced GSH depletion at 5 uM2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Structure-activity relationship study of vitamin k derivatives yields highly potent neuroprotective agents.
AID760285Effect on total ATP level in human Friedreich's ataxia lymphocytes at 25 uM after 48 hrs by bioluminescence assay relative to control2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
An optimized pyrimidinol multifunctional radical quencher.
AID754328Cytoprotective activity against diethyl maleate-induced oxidative stress in Friedreich's ataxia disease patient GM15850 cells assessed as cell viability at 0.5 uM preincubated for 15 hrs prior to diethyl maleate-challenge measured after 6 hrs by hemocytom2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID754324Cytoprotective activity against diethyl maleate-induced oxidative stress in human CCRF-CEM cells assessed as cell viability at 0.5 uM preincubated for 15 hrs prior to diethyl maleate-challenge measured after 6 hrs by hemocytometer-based assay2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID1432461Cytoprotective activity in FRDA patient derived lymphocytes cultured in glucose-free media supplemented with galactose assessed as total intracellular ATP levels at 5 uM after 48 hrs by luciferin-luciferase reaction-based bioluminescence assay relative to2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Influence of substituent heteroatoms on the cytoprotective properties of pyrimidinol antioxidants.
AID703754Preservation of mitochondrial membrane potential in diethyl maleate-treated human Friedreich's ataxia lymphocytes at 1 uM pre-incubated for 16 hrs before diethyl maleate challenge by FACS method (Rvb = 25%)2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Analysis of the structural and mechanistic factors in antioxidants that preserve mitochondrial function and confer cytoprotection.
AID754333Inhibition of NADH oxidase activity of bovine heart mitochondrial complexes 1, 2 and 3 at 5 uM after 5 mins by spectrophotometric analysis relative to control2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID703752Cytoprotection in diethyl maleate-treated human CCRF-CEM cells 0.1 uM incubated for 17 hrs before diethyl maleate challenge by trypan blue dye exclusion method (Rvb = 18 +/- 10%)2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Analysis of the structural and mechanistic factors in antioxidants that preserve mitochondrial function and confer cytoprotection.
AID1091094Termiticidal activity against Coptotermes formosanus placed on 1 % wt/wt compound treated filter paper assessed as termite mortality measured 21 days post compound exposure2008Journal of agricultural and food chemistry, Jun-11, Volume: 56, Issue:11
Activity of 1,4-benzoquinones against formosan subterranean termites (Coptotermes formosanus).
AID703748Inhibition of NADH oxidase activity in bovine heart sub-mitochondrial particles assessed as remaining enzyme activity at 5 uM by spectrophotometry relative to untreated control2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Analysis of the structural and mechanistic factors in antioxidants that preserve mitochondrial function and confer cytoprotection.
AID754320Cytoprotective activity against diethyl maleate-induced oxidative stress in Leigh's syndrome patient GM13740 cells assessed as cell viability at 2.5 uM preincubated for 15 hrs prior to diethyl maleate-challenge measured after 6 hrs by hemocytometer-based 2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID703753Preservation of mitochondrial membrane potential in diethyl maleate-treated human Friedreich's ataxia lymphocytes at 2.5 uM pre-incubated for 16 hrs before diethyl maleate challenge by FACS method (Rvb = 25%)2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Analysis of the structural and mechanistic factors in antioxidants that preserve mitochondrial function and confer cytoprotection.
AID1637919Electrochemical behavior of the compound assessed as redox potential (Eox) corrected toward saturated calomel reference electrode by cyclic voltammetry2019MedChemComm, Mar-01, Volume: 10, Issue:3
Amide linked redox-active naphthoquinones for the treatment of mitochondrial dysfunction.
AID738409Effect on cellular respiration in rat RGC5 cells assessed as increase in mitochondrial oxygen consumption at 3 uM after 1.5 hrs by fluorescence assay relative to vehicle-treated control2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID760289Effect on total ATP level in CoQ10-deficient human GM17932 cells at 25 uM after 48 hrs by bioluminescence assay relative to control2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
An optimized pyrimidinol multifunctional radical quencher.
AID738404Antioxidant activity in human CEM cells assessed as suppression of diethyl maleate-induced ROS production at 2.5 uM incubated for 16 hrs prior to diethyl maleate challenge measured after 1 hr by DCFH-DA staining-based flow cytometric analysis relative to 2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection.
AID1808089Stability of compound in mini gut model assessed as half life by LC-MS analysis2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach.
AID754353Antioxidant activity in human CCRF-CEM cells assessed as suppression of diethyl maleate-induced ROS generation preincubated for 18 hrs prior to diethyl maleate-challenge measured after 1 hr by FACS flow cytometric analysis in presence of DCFH-DA2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID1700565Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-blue assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Discovery of Novel 2-Aniline-1,4-naphthoquinones as Potential New Drug Treatment for Leber's Hereditary Optic Neuropathy (LHON).
AID754347Antioxidant activity in Leber's optic atrophy disease patient GM10744 cells assessed as suppression of diethyl maleate-induced ROS generation at 0.025 to 2.5 uM preincubated for 18 hrs prior to diethyl maleate-challenge measured after 1 hr by FACS flow cy2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID1700566Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-blue assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Discovery of Novel 2-Aniline-1,4-naphthoquinones as Potential New Drug Treatment for Leber's Hereditary Optic Neuropathy (LHON).
AID703747Inhibition of NADH oxidase activity in bovine heart sub-mitochondrial particles assessed as remaining enzyme activity at 1 uM by spectrophotometry relative to untreated control2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Analysis of the structural and mechanistic factors in antioxidants that preserve mitochondrial function and confer cytoprotection.
AID729238Inhibition of tPMET complex in human HL60 cells after 30 mins by WST-1/mPMS reduction assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Anti-leukemic activity of ubiquinone-based compounds targeting trans-plasma membrane electron transport.
AID729232Cell cycle arrest in human HL60 cells assessed as accumulation at G2 phase at 30 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 22 %)2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Anti-leukemic activity of ubiquinone-based compounds targeting trans-plasma membrane electron transport.
AID1700575Cytotoxicity against human HepG2 cells assessed as cell viability at 25 uM incubated for 24 hrs by Celltiter-blue assay relative to control2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Discovery of Novel 2-Aniline-1,4-naphthoquinones as Potential New Drug Treatment for Leber's Hereditary Optic Neuropathy (LHON).
AID760280Decrease in mitochondrial ATP level in CoQ10-deficient human Friedreich's ataxia lymphocytes at 5 uM after 6 days by bioluminescence assay in presence of 4-nitrobenzoate2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
An optimized pyrimidinol multifunctional radical quencher.
AID754339Effect on total ATP level in Leber's optic atrophy disease patient GM10744 cells at 10 uM after 48 hrs by bioluminescence assay relative to control2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID729230Cell cycle arrest in human mitochondrial gene-knockout HL60 cells assessed as accumulation at G1 phase at 30 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 55 %)2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Anti-leukemic activity of ubiquinone-based compounds targeting trans-plasma membrane electron transport.
AID754321Cytoprotective activity against diethyl maleate-induced oxidative stress in Alzheimer's disease patient AG06849 cells assessed as cell viability at 2.5 uM preincubated for 15 hrs prior to diethyl maleate-challenge measured after 6 hrs by hemocytometer-bas2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID754352Antioxidant activity in human CCRF-CEM cells assessed as suppression of diethyl maleate-induced ROS generation at 0.025 to 2.5 uM preincubated for 18 hrs prior to diethyl maleate-challenge measured after 1 hr by FACS flow cytometric analysis in presence o2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID760292Cytoprotective activity against BSO-induced cell death in human Friedreich's ataxia lymphocytes preincubated for 12 hrs prior to BSO-treatment measured after 48 hrs by luminescence assay2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
An optimized pyrimidinol multifunctional radical quencher.
AID754334Inhibition of NADH oxidase activity of bovine heart mitochondrial complexes 1, 2 and 3 at 1 uM after 5 mins by spectrophotometric analysis relative to control2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID1432463Cytoprotective activity in FRDA patient derived lymphocytes cultured in glucose-free media supplemented with galactose assessed as total intracellular ATP levels at 25 uM after 48 hrs by luciferin-luciferase reaction-based bioluminescence assay relative t2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Influence of substituent heteroatoms on the cytoprotective properties of pyrimidinol antioxidants.
AID729237Inhibition of tPMET complex in human mitochondrial gene-knockout HL60 cells after 30 mins by WST-1/mPMS reduction assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Anti-leukemic activity of ubiquinone-based compounds targeting trans-plasma membrane electron transport.
AID754325Cytoprotective activity against diethyl maleate-induced oxidative stress in Parkinson's disease patient GM15010 cells assessed as cell viability at 0.5 uM preincubated for 15 hrs prior to diethyl maleate-challenge measured after 6 hrs by hemocytometer-bas2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID703759Inhibition of NADH oxidase activity in bovine heart sub-mitochondrial particles assessed as remaining enzyme activity at 10 uM by spectrophotometry relative to untreated control2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Analysis of the structural and mechanistic factors in antioxidants that preserve mitochondrial function and confer cytoprotection.
AID738406Effect on cellular respiration in rat RGC5 cells assessed as increase in mitochondrial oxygen consumption at 10 uM after 24 hrs by fluorescence assay relative to vehicle-treated control2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection.
AID760281Decrease in mitochondrial ATP level in CoQ10-deficient human Friedreich's ataxia lymphocytes at 5 uM after 6 days by bioluminescence assay2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
An optimized pyrimidinol multifunctional radical quencher.
AID1700551Suppression of rotenone-induced ATP depletion in human HepG2 cells incubated for 2 hrs by Celltiter-Glo assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Discovery of Novel 2-Aniline-1,4-naphthoquinones as Potential New Drug Treatment for Leber's Hereditary Optic Neuropathy (LHON).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID729233Cell cycle arrest in human HL60 cells assessed as accumulation at G1 phase at 30 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 38 %)2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Anti-leukemic activity of ubiquinone-based compounds targeting trans-plasma membrane electron transport.
AID1526043Inhibition of N-terminal His6 tagged human sirtuin 2 (25 to 389 residues) using Cbz-Lys(acetyl)-AMC as substrate after 4 hrs in presence of NAD+ by homogeneous fluorescence based analysis2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from
AID703757Inhibition of lipid peroxidation in diethyl maleate-treated human Friedreich's ataxia lymphocytes at 5 uM pre-incubated for 16 hrs before diethyl maleate challenge by FACS method relative to untreated control2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Analysis of the structural and mechanistic factors in antioxidants that preserve mitochondrial function and confer cytoprotection.
AID754342Effect on total ATP level in CoQ10-deficient human GM17932 cells at 10 uM after 48 hrs by bioluminescence assay relative to control2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID760286Effect on total ATP level in human Friedreich's ataxia lymphocytes at 10 uM after 48 hrs by bioluminescence assay relative to control2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
An optimized pyrimidinol multifunctional radical quencher.
AID738405Antioxidant activity in human CEM cells assessed as suppression of diethyl maleate-induced ROS production at 1 uM incubated for 16 hrs prior to diethyl maleate challenge measured after 1 hr by DCFH-DA staining-based flow cytometric analysis relative to un2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection.
AID738403Blockade of diethyl maleate-induced mitochondrial membrane potential collapse in human CEM cells assessed as cells with intact mitochondrial membrane potential at 0.5 uM incubated for 16 hrs prior to diethyl maleate challenge measured after 120 mins by TM2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection.
AID703756Inhibition of diethyl maleate-induced ROS production in human CCRF-CEM cells at 0.25 to 2.5 uM incubated for 16 hrs by DCFH-DA dye staining based FACS method2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Analysis of the structural and mechanistic factors in antioxidants that preserve mitochondrial function and confer cytoprotection.
AID738400Cytoprotective effect in human CEM cells assessed as reduction of diethyl maleate-induced oxidative stress measured cell viability at 0.5 uM incubated for 17 hrs prior to diethyl maleate challenge measured after 6 hrs by trypan blue exclusion assay relati2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection.
AID760283Decrease in total ATP level in human Friedreich's ataxia lymphocytes after 48 hrs by bioluminescence assay2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
An optimized pyrimidinol multifunctional radical quencher.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1700563Suppression of rotenone-induced ATP depletion in human HepG2 cells assessed as rescue of ATP level at 5 uM incubated for 2 hrs in presence of complex III inhibitor myxothiazol by Celltiter-Glo assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Discovery of Novel 2-Aniline-1,4-naphthoquinones as Potential New Drug Treatment for Leber's Hereditary Optic Neuropathy (LHON).
AID754335Effect on total ATP level in Friedreich's ataxia disease patient GM15850 cells at 25 uM after 48 hrs by bioluminescence assay relative to control2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID754331Inhibition of NADH-ubiquinone oxidoreductase in bovine heart mitochondria after 5 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID754323Cytoprotective activity against diethyl maleate-induced oxidative stress in Leber's optic atrophy disease patient GM10744 cells assessed as cell viability at 2.5 uM preincubated for 15 hrs prior to diethyl maleate-challenge measured after 6 hrs by hemocyt2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID1526021Inhibition of recombinant Schistosoma mansoni sirtuin 2 (21 to 322 residues) expressed in Escherichia coli BL21(DE3) cells using ZMAL as substrate after 1 hr in presence of NAD+ by homogeneous fluorescence based analysis2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID754338Effect on total ATP level in Leber's optic atrophy disease patient GM10744 cells at 25 uM after 48 hrs by bioluminescence assay relative to control2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID754348Antioxidant activity in Alzheimer's disease patient AG06849 cells assessed as suppression of diethyl maleate-induced ROS generation at 0.025 to 2.5 uM preincubated for 18 hrs prior to diethyl maleate-challenge measured after 1 hr by FACS flow cytometric a2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID760290Effect on total ATP level in CoQ10-deficient human GM17932 cells at 10 uM after 48 hrs by bioluminescence assay relative to control2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
An optimized pyrimidinol multifunctional radical quencher.
AID754346Effect on total ATP level in Leber's optic atrophy disease patient GM10744 cells after 48 hrs by bioluminescence assay2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID1808092Drug metabolism in human gut microbes assessed as metabolite formation by LC-MS/MS analysis2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach.
AID1700574Suppression of rotenone-induced ATP depletion in human HepG2 cells assessed as rescue of ATP level incubated for 2 hrs by Celltiter-Glo assay relative to control2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Discovery of Novel 2-Aniline-1,4-naphthoquinones as Potential New Drug Treatment for Leber's Hereditary Optic Neuropathy (LHON).
AID703758Inhibition of lipid peroxidation in diethyl maleate-treated human Friedreich's ataxia lymphocytes at 2.5 uM pre-incubated for 16 hrs before diethyl maleate challenge by FACS method relative to untreated control2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Analysis of the structural and mechanistic factors in antioxidants that preserve mitochondrial function and confer cytoprotection.
AID738407Effect on cellular respiration in rat RGC5 cells assessed as increase in mitochondrial oxygen consumption at 3 uM after 24 hrs by fluorescence assay relative to vehicle-treated control2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection.
AID703755Preservation of mitochondrial membrane potential in diethyl maleate-treated human Friedreich's ataxia lymphocytes at 0.5 uM pre-incubated for 16 hrs before diethyl maleate challenge by FACS method (Rvb = 25%)2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Analysis of the structural and mechanistic factors in antioxidants that preserve mitochondrial function and confer cytoprotection.
AID1432460Cytoprotective activity in FRDA patient derived lymphocytes cultured in glucose-free media supplemented with galactose assessed as total intracellular ATP levels at 1 uM after 48 hrs by luciferin-luciferase reaction-based bioluminescence assay relative to2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Influence of substituent heteroatoms on the cytoprotective properties of pyrimidinol antioxidants.
AID738401Cytoprotective effect in human CEM cells assessed as reduction of diethyl maleate-induced oxidative stress measured cell viability at 0.1 uM incubated for 17 hrs prior to diethyl maleate challenge measured after 6 hrs by trypan blue exclusion assay relati2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID754326Cytoprotective activity against diethyl maleate-induced oxidative stress in Leigh's syndrome patient GM13740 cells assessed as cell viability at 0.5 uM preincubated for 15 hrs prior to diethyl maleate-challenge measured after 6 hrs by hemocytometer-based 2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID1432457Cytoprotective activity in DEM-treated FRDA patient derived lymphocytes assessed as preservation of mitochondrial inner membrane potential at 0.5 uM pretreated for 16 hrs followed by DEM addition measured after 120 mins by TMRM dye-based flow cytometric a2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Influence of substituent heteroatoms on the cytoprotective properties of pyrimidinol antioxidants.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1432456Cytoprotective activity in DEM-treated FRDA patient derived lymphocytes assessed as preservation of mitochondrial inner membrane potential at 2.5 uM pretreated for 16 hrs followed by DEM addition measured after 120 mins by TMRM dye-based flow cytometric a2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Influence of substituent heteroatoms on the cytoprotective properties of pyrimidinol antioxidants.
AID611404Cytoprotectant activity against L-buthionine-(S,R)-sulfoximine-induced cell death in Friedreich ataxia patient fibroblasts assessed as increase of cell viability2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID738398Cytoprotective effect in human CEM cells assessed as reduction of diethyl maleate-induced oxidative stress measured cell viability at 5 uM incubated for 17 hrs prior to diethyl maleate challenge measured after 6 hrs by trypan blue exclusion assay relative2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection.
AID754329Cytoprotective activity against diethyl maleate-induced oxidative stress in Leber's optic atrophy disease patient GM10744 cells assessed as cell viability at 0.5 uM preincubated for 15 hrs prior to diethyl maleate-challenge measured after 6 hrs by hemocyt2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID760291Effect on total ATP level in CoQ10-deficient human GM17932 cells at 5 uM after 48 hrs by bioluminescence assay relative to control2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
An optimized pyrimidinol multifunctional radical quencher.
AID754330Inhibition of NADH-ubiquinone oxidoreductase in bovine heart mitochondria after 5 mins by spectrophotometric analysis relative to control2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID754340Effect on total ATP level in Leber's optic atrophy disease patient GM10744 cells at 5 uM after 48 hrs by bioluminescence assay relative to control2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID754337Effect on total ATP level in Friedreich's ataxia disease patient GM15850 cells at 5 uM after 48 hrs by bioluminescence assay relative to control2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID760293Cytoprotective activity against diethyl maleate-induced loss of mitochondrial membrane integrity in human Friedreich's ataxia lymphocytes at 500 nM incubated overnight prior to diethyl maleate-treatment measured after 140 mins by TMRM staining-based FACS 2013ACS medicinal chemistry letters, Aug-08, Volume: 4, Issue:8
An optimized pyrimidinol multifunctional radical quencher.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID754336Effect on total ATP level in Friedreich's ataxia disease patient GM15850 cells at 10 uM after 48 hrs by bioluminescence assay relative to control2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID502265Cytoprotective activity against diethyl maleate-induced cell death in human CEM cells assessed as cell viability at 0.5 uM treated 18 hrs before diethyl maleate challenge measured after 4 hrs by trypan blue assay2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Synthesis and characterization of mitoQ and idebenone analogues as mediators of oxygen consumption in mitochondria.
AID729234Cell cycle arrest in human HL60 cells assessed as accumulation at sub G1 phase at 30 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 11 %)2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Anti-leukemic activity of ubiquinone-based compounds targeting trans-plasma membrane electron transport.
AID1091096Termiticidal activity against Coptotermes formosanus placed on 1 % wt/wt compound treated filter paper assessed as termite mortality measured 3 days post compound exposure2008Journal of agricultural and food chemistry, Jun-11, Volume: 56, Issue:11
Activity of 1,4-benzoquinones against formosan subterranean termites (Coptotermes formosanus).
AID1432464Metabolic stability in bovine liver microsomes assessed as compound recovery at 25 uM after 30 mins in presence of beta-NADPH by HPLC method2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Influence of substituent heteroatoms on the cytoprotective properties of pyrimidinol antioxidants.
AID738402Blockade of diethyl maleate-induced mitochondrial membrane potential collapse in human CEM cells assessed as cells with intact mitochondrial membrane potential at 1 uM incubated for 16 hrs prior to diethyl maleate challenge measured after 120 mins by TMRM2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection.
AID312786Inhibition of NADH-induced lipid peroxidation in rat brain microsome2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Synthesis and evaluation of 2'-hydroxyethyl trans-apovincaminate derivatives as antioxidant and cognitive enhancer agents.
AID729236Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Anti-leukemic activity of ubiquinone-based compounds targeting trans-plasma membrane electron transport.
AID502266Cytoprotective activity against diethyl maleate-induced cell death in human CEM cells assessed as cell viability at 0.1 uM treated 18 hrs before diethyl maleate challenge measured after 4 hrs by trypan blue assay2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Synthesis and characterization of mitoQ and idebenone analogues as mediators of oxygen consumption in mitochondria.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1637921Electrochemical behavior of the compound assessed as redox potential (Ered) corrected toward saturated calomel reference electrode by cyclic voltammetry2019MedChemComm, Mar-01, Volume: 10, Issue:3
Amide linked redox-active naphthoquinones for the treatment of mitochondrial dysfunction.
AID754332Inhibition of NADH oxidase activity of bovine heart mitochondrial complexes 1, 2 and 3 at 10 uM after 5 mins by spectrophotometric analysis relative to control2013Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4
Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (431)

TimeframeStudies, This Drug (%)All Drugs %
pre-199050 (11.60)18.7374
1990's71 (16.47)18.2507
2000's86 (19.95)29.6817
2010's164 (38.05)24.3611
2020's60 (13.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.89 (24.57)
Research Supply Index6.20 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index107.36 (26.88)
Search Engine Supply Index3.75 (0.95)

This Compound (37.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials46 (10.27%)5.53%
Reviews52 (11.61%)6.00%
Case Studies30 (6.70%)4.05%
Observational3 (0.67%)0.25%
Other317 (70.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (32)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Idebenone in the Treatment of Early-stage Parkinson's Disease With Motor and Non-motor Symptoms [NCT03727295]Phase 4180 participants (Anticipated)Interventional2019-01-01Not yet recruiting
An Open-label Study to Assess the Potential for Pre-systemic Inhibition of Cytochrome P450 3A4 (CYP3A) by Idebenone in Healthy Male Subjects Using Midazolam as a Substrate [NCT02887443]Phase 132 participants (Actual)Interventional2016-09-30Completed
Study of the Therapeutic Effects of Naohuan Dan and Idebenone in Treating Mild Cognitive Impairment With Kidney Deficiency and Phlegm Stasis [NCT05931029]64 participants (Actual)Observational2019-05-01Completed
A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Who Completed the SIDEROS Study [NCT03603288]Phase 3161 participants (Actual)Interventional2018-07-04Terminated(stopped due to Interim analysis concluded to futility of main study SIDEROS (SNT-III-012))
A Randomized, Double-blinded, Placebo-controlled Trial of Idebenone in the Prevention of Episodic Migraine [NCT04151472]Phase 3180 participants (Anticipated)Interventional2021-12-08Recruiting
A Phase III Open-Label, Single-Group, Extension Study to Obtain Long-Term Safety and Tolerability Data of Idebenone in the Treatment of Friedreich's Ataxia Patients. [NCT00993967]Phase 3200 participants (Actual)Interventional2007-06-30Completed
A Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Patients With Leber's Hereditary Optic Neuropathy [NCT00747487]Phase 285 participants (Actual)Interventional2007-11-30Completed
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids [NCT02814019]Phase 3255 participants (Actual)Interventional2016-09-30Terminated(stopped due to Interim analysis concluded to futility)
A Randomized, Double-blind, Multi-center Clinical Study of the Efficacy of Idebenone in the Treatment of Primary Rapid Eye Movement Sleep Behavior Disorder Into Synucleinopathies [NCT04534023]Phase 2142 participants (Anticipated)Interventional2020-09-01Recruiting
A Pilot Study to Treat Adults With Non-Alcoholic Steatohepatitis With Oral Idebenone [NCT04669158]Phase 1/Phase 245 participants (Actual)Interventional2021-07-30Active, not recruiting
A Phase II Open-label Extension Study to Obtain Long-term Safety, Tolerability and Efficacy Data of Idebenone in the Treatment of Duchenne Muscular Dystrophy - Extension to Study SNT-II-001 [NCT00758225]Phase 221 participants (Anticipated)Interventional2008-09-30Completed
A Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber's Hereditary Optic Neuropathy (LHON) [NCT02771379]229 participants (Actual)Observational2016-09-30Completed
A Multi-center, Randomized, Double-blind, Placebo-controlled Parallel Pilot Study to Evaluate Safety and Efficacy of Oral Idebenone for Preventive Treatment of Migraine in Adult Migraine Patients [NCT05411978]Phase 4900 participants (Anticipated)Interventional2022-05-09Recruiting
A Phase III Open-Label, Single Group Extension Study of the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients [NCT00697073]Phase 368 participants (Actual)Interventional2008-07-31Completed
Non-randomized Control Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease Patients [NCT04071639]Phase 160 participants (Anticipated)Interventional2020-03-12Recruiting
Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis [NCT00950248]Phase 1/Phase 285 participants (Actual)Interventional2009-11-01Completed
A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease (SEASEiPPD) [NCT04152655]Phase 2/Phase 3180 participants (Anticipated)Interventional2020-01-01Recruiting
Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study [NCT04381091]0 participants Expanded AccessNo longer available
Expanded Access Protocol (EAP) of Idebenone in Patients With Duchenne Muscular Dystrophy [NCT03433807]0 participants Expanded AccessNo longer available
Phase I Clinical Trial to Establish the Maximum Tolerated Dose of Idebenone in Children, Adolescents, and Adults With Friedreich's Ataxia [NCT00015808]Phase 1100 participants Interventional2001-05-31Completed
A Six Month Double-Blind, Placebo-Controlled Phase 2 Clinical Trial to Determine the Safety and Efficacy of Idebenone Administered to Patients With Friedreich's Ataxia [NCT00229632]Phase 251 participants (Actual)Interventional2005-09-27Completed
A Phase III Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in 10-18 Year Old Patients With Duchenne Muscular Dystrophy [NCT01027884]Phase 365 participants (Actual)Interventional2009-07-31Completed
External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment With Raxone® in Leber's Hereditary Optic Neuropathy (LHON) [NCT02774005]Phase 4199 participants (Actual)Interventional2016-05-31Completed
A Phase IIa Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis and Stroke-like Episodes [NCT00887562]Phase 227 participants (Actual)Interventional2009-05-31Completed
A Phase III Double-blind, Randomised, Placebo-controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients [NCT00905268]Phase 3232 participants (Actual)Interventional2006-04-30Completed
A Phase III Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients [NCT00537680]Phase 370 participants (Actual)Interventional2007-12-31Completed
Phase 1B Clinical Trial to Establish the Safety and Tolerability of a Multiple-Dose Regimen of Idebenone Administered to Patients With Friedreich's Ataxia [NCT00078481]Phase 116 participants Interventional2004-02-29Completed
[NCT01495715]Phase 30 participants (Actual)InterventionalWithdrawn
A Phase IIIb Double-Blind, Randomised, Placebo-Controlled Study of Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone [NCT01303406]Phase 329 participants (Actual)Interventional2011-04-30Completed
Open Label Extension Trial of Idebenone for Primary Progressive Multiple Sclerosis [NCT01854359]Phase 1/Phase 261 participants (Actual)Interventional2013-03-12Completed
Clinical Multi-center Study of Mitochondrial Brain Protective Agent Idebenone in the Prevention of Post-stroke Epilepsy [NCT05987397]Phase 42,700 participants (Anticipated)Interventional2023-07-05Recruiting
A Phase IIa Double Blind, Randomised, Placebo Controlled, Single Centre Study at the University of Leuven to Assess the Efficacy and Tolerability of Idebenone in 8 - 16 Year Old Males With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy [NCT00654784]Phase 221 participants (Actual)Interventional2005-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00537680 (12) [back to overview]Absolute Change From Baseline to Week 24 in Left Ventricular Mass Index (LVMI)
NCT00537680 (12) [back to overview]Percent Change From Baseline to Week 24 in the Thickness of the Posterior Wall (PW) of the Left Ventricle
NCT00537680 (12) [back to overview]Percent Change From Baseline to Week 24 in the Thickness of the Interventricular Septum (IVS)
NCT00537680 (12) [back to overview]Percent Change From Baseline to Week 24 in the Relative Wall Thickness (RWT) of the Left Ventricle
NCT00537680 (12) [back to overview]Percent Change From Baseline to Week 24 in Left Ventricular Mass Index
NCT00537680 (12) [back to overview]Change in the International Cooperative Ataxia Rating Scale (ICARS) From Baseline Assessment to Week 24
NCT00537680 (12) [back to overview]Change in the International Cooperative Ataxia Rating Scale (ICARS) From Baseline Assessment to Week 12
NCT00537680 (12) [back to overview]Change in Friedreich's Ataxia Rating Scale (FARS) Scores From Baseline to Week 24
NCT00537680 (12) [back to overview]Activities of Daily Living (ADL) of Friedreich's Ataxia Rating Scale (FARS), Change in ADL (Total Score ) From Baseline to Week 24
NCT00537680 (12) [back to overview]Absolute Change From Baseline to Week 24 in the Thickness of the Posterior Wall (PW) of the Left Ventricle
NCT00537680 (12) [back to overview]Absolute Change From Baseline to Week 24 in the Thickness of the Interventricular Septum (IVS)
NCT00537680 (12) [back to overview]Absolute Change From Baseline to Week 24 in the Relative Wall Thickness (RWT) of the Left Ventricle
NCT00654784 (1) [back to overview]The Relative Change in Peak Systolic Radial Strain of the Left Ventricle (LV) Inferolateral Wall From Baseline (at Screening) to Week 52, Assessed by Color Doppler Myocardial Imaging (CDMI).
NCT00697073 (4) [back to overview]Change in ICARS
NCT00697073 (4) [back to overview]FARS (Friedreich's Ataxia Rating Scale)
NCT00697073 (4) [back to overview]Frequency/Number of Mild, Moderate, and Severe Adverse Events
NCT00697073 (4) [back to overview]Nature of Adverse Events
NCT00887562 (3) [back to overview]Mean Change in Cerebral Lactate Concentration (as Measured by Magnetic Resonance Spectroscopy)
NCT00887562 (3) [back to overview]Mean Change in Score on the Fatigue Severity Scale (FSS)
NCT00887562 (3) [back to overview]Mean Change in Venous Lactate Concentration
NCT00905268 (6) [back to overview]Change in Peak Systolic Strain Rate From Baseline to Week 52
NCT00905268 (6) [back to overview]Change in Peak Workload From Baseline to Week 52
NCT00905268 (6) [back to overview]Proportion of Patients Improving (Responding) on ICARS by a Clinically Relevant Margin
NCT00905268 (6) [back to overview]Proportion of Patients Improving on Left Ventricular Peak Systolic Strain Rate or Showing a Reduction in Left Ventricular Mass Index (LVMI) With no Worsening in Strain Rate
NCT00905268 (6) [back to overview]Absolute Change in Friedreich's Ataxia Rating Scale (FARS) Scores From Baseline Assessment to Week 52
NCT00905268 (6) [back to overview]Absolute Change in International Cooperative Ataxia Rating Scale (ICARS) Scores From Baseline Assessment to Week 52
NCT00950248 (7) [back to overview]Change in Slopes of 25FW Time From Baseline to Treatment Phase
NCT00950248 (7) [back to overview]Change in Slopes of 9HPT Time From Baseline to Treatment Phase
NCT00950248 (7) [back to overview]Change in Slopes of EDSS From Baseline to Treatment Phase
NCT00950248 (7) [back to overview]Change in the AUC of Individualized Rates of Enlargement of Ventricular Volume From Baseline to Treatment Phase
NCT00950248 (7) [back to overview]Change in the Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) From Baseline to Treatment Phase
NCT00950248 (7) [back to overview]Change in Slopes of SNRS From Baseline to Treatment Phase on
NCT00950248 (7) [back to overview]Disability Progression Measured by EDSS-plus
NCT00993967 (2) [back to overview]Measures of Safety and Tolerability: Nature and Frequency of Adverse Events (AEs)
NCT00993967 (2) [back to overview]Absolute Change in The International Cooperative Ataxia Rating Scale (ICARS)
NCT01027884 (5) [back to overview]Change From Baseline to Week 52 in Muscle Strength
NCT01027884 (5) [back to overview]Percentage of Patients Reporting Adverse Events
NCT01027884 (5) [back to overview]Change From Baseline to Week 52 in Quality of Life Assessed by PedsQL™ Paediatric Quality of Life Inventory
NCT01027884 (5) [back to overview]Change From Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Week 52
NCT01027884 (5) [back to overview]Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52
NCT01303406 (2) [back to overview]Comparison of the Percentage of Participants Randomised to Idebenone and Placebo Who Withdrew Early Due to Recurrence or Worsening of FRDA Symptoms
NCT01303406 (2) [back to overview]Patient Assessment of Treatment Assignment: Comparison of the Proportions of Patients Randomised to Idebenone and Placebo Who Assessed That They Received Idebenone
NCT01854359 (5) [back to overview]Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE)
NCT01854359 (5) [back to overview]Change in Slopes of Scripps Neurological Rating Scale (SNRS) Score
NCT01854359 (5) [back to overview]Slopes of 25 Foot Walk (25FW) Time
NCT01854359 (5) [back to overview]Slopes of 9 Hole Peg Test (9HPT) Time
NCT01854359 (5) [back to overview]Slopes of Expanded Disability Status Scale (EDSS) Score
NCT02774005 (3) [back to overview]Proportion (Number) of Eyes With Clinically Relevant Recovery of Visual Acuity From Baseline
NCT02774005 (3) [back to overview]Components of the Primary Endpoint: Proportion of Eyes With Clinically Relevant Recovery (CRR) of VA From Baseline at Month 12 Compared to Matching External National History (NH) Control Group
NCT02774005 (3) [back to overview]Components of the Primary Endpoint: Proportion of Eyes in Which Baseline Visual Acuity (VA) Better Than 1.0 logMAR Was Maintained at Month 12 (Clinically Relevant Stabilization) Compared to Matching External NH Control Group

Absolute Change From Baseline to Week 24 in Left Ventricular Mass Index (LVMI)

To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months

Interventiong/m2 (Mean)
Mid Dose Idebenone-3.06
High Dose Idebenone-2.56
Placebo-1.26

[back to top]

Percent Change From Baseline to Week 24 in the Thickness of the Posterior Wall (PW) of the Left Ventricle

To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months

Intervention% change (Mean)
Mid Dose Idebenone-0.075
High Dose Idebenone0.12
Placebo-3.04

[back to top]

Percent Change From Baseline to Week 24 in the Thickness of the Interventricular Septum (IVS)

To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 24 weeks

Intervention% change (Mean)
Mid Dose Idebenone1.3
High Dose Idebenone2.6
Placebo7.8

[back to top]

Percent Change From Baseline to Week 24 in the Relative Wall Thickness (RWT) of the Left Ventricle

To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months

Intervention% change (Mean)
Mid Dose Idebenone-3.32
High Dose Idebenone1.53
Placebo2.65

[back to top]

Percent Change From Baseline to Week 24 in Left Ventricular Mass Index

To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months

Intervention% change (Mean)
Mid Dose Idebenone-4.5
High Dose Idebenone-4.9
Placebo-1.7

[back to top]

Change in the International Cooperative Ataxia Rating Scale (ICARS) From Baseline Assessment to Week 24

"International Cooperative Ataxia Rating Scale (ICARS):~ICARS consists of a one-hundred-point semi-quantitative scale based upon 19 simple testing manoeuvres compartmentalized into postural and stance disorders, limb ataxia, dysarthria and oculomotor disorders and has been previously used in this patient population with good inter-rater reliability.~Minimum score: 0, maximum score 100, higher score indicates greater impairment~Calculation details: ICARS score at week 24 minus ICARS score baseline" (NCT00537680)
Timeframe: baseline and 6 months

InterventionICARS points (Mean)
Mid Dose Idebenone-2.5
High Dose Idebenone-2.4
Placebo-1.3

[back to top]

Change in the International Cooperative Ataxia Rating Scale (ICARS) From Baseline Assessment to Week 12

"To compare the efficacy of 3 months' treatment with 2 different doses of idebenone with that of placebo on neurological impairment as assessed by the International Cooperative Ataxia Rating Scale (ICARS)~International Cooperative Ataxia Rating Scale (ICARS):~ICARS consists of a one-hundred-point semi-quantitative scale based upon 19 simple testing manoeuvres compartmentalized into postural and stance disorders, limb ataxia, dysarthria and oculomotor disorders and has been previously used in this patient population with good inter-rater reliability.~Minimum score: 0, maximum score 100, higher score indicates greater impairment~Calculation details: ICARS score at week 12 minus ICARS score baseline" (NCT00537680)
Timeframe: baseline and 12 weeks

InterventionICARS points (Mean)
Mid Dose Idebenone-1.5
High Dose Idebenone-1.6
Placebo-3.0

[back to top]

Change in Friedreich's Ataxia Rating Scale (FARS) Scores From Baseline to Week 24

"To compare the efficacy of 6 months' treatment with 2 different doses of idebenone with that of placebo on neurological function as assessed by the Friedreich's Ataxia Rating Scale (FARS)~FARS consists of a 25 manoeuvre exam along with 4 quantitative performance measures. The neurological exam covers bulbar function, upper limb coordination, lower limb coordination, peripheral nervous system function, deep tendon reflexes, stability and gait. The use of FARS has been recently validated as a sensitive scale for this population.~The FARS exam scores can be added to make a total score ranging from 0 to 159. A higher score indicates a greater level of disability.~Calculation details FARS score at week 24 minus FARS score baseline" (NCT00537680)
Timeframe: baseline and 6 months

InterventionFARS score (Mean)
Mid Dose Idebenone-1.6
High Dose Idebenone-1.2
Placebo0.6

[back to top]

Activities of Daily Living (ADL) of Friedreich's Ataxia Rating Scale (FARS), Change in ADL (Total Score ) From Baseline to Week 24

"To compare the efficacy of 6 months' treatment with 2 different doses of idebenone with that of placebo on Activities of Daily Living (ADL) assessed by the ADL scale of the Friedreich's Ataxia Rating Scale (FARS)~score 0 to 36, higher score indicates greater impairment" (NCT00537680)
Timeframe: baseline and 6 months

InterventionADL points (Mean)
Mid Dose Idebenone0.2
High Dose Idebenone0.6
Placebo1.0

[back to top]

Absolute Change From Baseline to Week 24 in the Thickness of the Posterior Wall (PW) of the Left Ventricle

To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months

Interventioncm (Mean)
Mid Dose Idebenone-0.018
High Dose Idebenone-0.004
Placebo-0.038

[back to top]

Absolute Change From Baseline to Week 24 in the Thickness of the Interventricular Septum (IVS)

To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months

Interventioncm (Mean)
Mid Dose Idebenone-0.014
High Dose Idebenone0.021
Placebo0.063

[back to top]

Absolute Change From Baseline to Week 24 in the Relative Wall Thickness (RWT) of the Left Ventricle

To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months

Interventioncm (Mean)
Mid Dose Idebenone-0.032
High Dose Idebenone0.007
Placebo0.010

[back to top]

The Relative Change in Peak Systolic Radial Strain of the Left Ventricle (LV) Inferolateral Wall From Baseline (at Screening) to Week 52, Assessed by Color Doppler Myocardial Imaging (CDMI).

"Assessing the peak systolic radial strain of the left ventricle inferolateral wall is used to characterize the cardiac involvement in the DMD patients.~Color Doppler Myocardial Imaging technique is used to quantify regional myocardial function.~The cardiac involvement in DMD is characterized by degeneration, atrophy and fibrosis of the myocardium, leading to dilated cardiomyopathy. The process begins in the posterolateral wall of the left ventricle, with septal involvement appearing at later stages." (NCT00654784)
Timeframe: baseline and Week 52

Intervention% change in peak systolic (Mean)
Idebenone 450 mg/ Day104.4
Placebo28.9

[back to top]

Change in ICARS

"International Cooperative Ataxia Rating Scale (ICARS):~ICARS consists of a one-hundred-point semi-quantitative scale based upon 19 simple testing manoeuvres compartmentalized into postural and stance disorders, limb ataxia, dysarthria and oculomotor disorders and has been previously used in this patient population with good inter-rater reliability.~A total score of 0 points represents the best possible score, and a value of 100 points is the worst possible score. Therefore, a negative change in ICARS score represents an improvement. A higher score also indicates more disability." (NCT00697073)
Timeframe: baseline and 12 months

Interventionunits on a scale (Mean)
High Dose Idebenone1.1

[back to top]

FARS (Friedreich's Ataxia Rating Scale)

FARS consists of a 25 manoeuvre exam along with 4 quantitative performance measures. The neurological exam covers bulbar function, upper limb coordination, lower limb coordination, peripheral nervous system function, deep tendon reflexes, stability and gait. The use of FARS has been recently validated as a sensitive scale for this population. The FARS consists of three subscales, comprising a general score for ataxia, a score for activities of daily living (ADL) and a neurological examination. The scores can be added to make a total score ranging from 0 to 159. A higher score indicates a greater level of disability. (NCT00697073)
Timeframe: baseline and 12 Months

Interventionunits on a scale (Mean)
High Dose Idebenone2.3

[back to top]

Frequency/Number of Mild, Moderate, and Severe Adverse Events

(NCT00697073)
Timeframe: 12 months

Interventionevents (Number)
mildmoderatesevere
High Dose Idebenone30324

[back to top]

Nature of Adverse Events

(NCT00697073)
Timeframe: 12 Months

Interventionevents (Number)
Infections and InfestationsGastrointestinal DisordersMusculoskeletal and Connective Tissue Disorders
High Dose Idebenone1179775

[back to top]

Mean Change in Cerebral Lactate Concentration (as Measured by Magnetic Resonance Spectroscopy)

To compare the efficacy of 1 month treatment with 2 different doses of idebenone with that of placebo on cerebral lactate concentration as measured by magnetic resonance spectroscopy (MRS) (NCT00887562)
Timeframe: Up to 4 weeks from baseline

InterventionIU (Mean)
Idebenone 900 mg/Day-0.09
Idebenone 2250 mg/Day0.16
Placebo-0.49

[back to top]

Mean Change in Score on the Fatigue Severity Scale (FSS)

"To assess changes following 1 month treatment with 2 different doses of idebenone with that of placebo in fatigue as assessed by the Fatigue Severity Scale (FSS).~Scale score minimum is 9 (least fatigue) and maximum is 63 (maximum fatigue). Scores of 36 or less indicate possibility that patient may not be suffering from fatigue, while scores 36 and over suggest suffering from fatigue" (NCT00887562)
Timeframe: Baseline and Week 4

Interventionunits on a scale (Mean)
900 mg/Day-3.8
2250 mg/Day-1.3
Placebo4.3

[back to top]

Mean Change in Venous Lactate Concentration

To compare the efficacy of 1 month treatment with 2 different doses of idebenone with that of placebo on venous lactate concentration (NCT00887562)
Timeframe: Up to 4 weeks from baseline

InterventionmM/L (Mean)
Idebenone 900 mg/Day-0.24
Idebenone 2250 mg/Day0.7
Placebo-0.46

[back to top]

Change in Peak Systolic Strain Rate From Baseline to Week 52

Mean Change of Peak systolic longitudinal strain rate (PSLSR) from Baseline to Week 52 in subjects with cardiac involvement (FRDA-CM criteria), where positive value in PSLSR is a deterioration and negative value an improvement. (NCT00905268)
Timeframe: 1 year

Intervention1/s (Mean)
Group A: Idebenone0.007
Group B: Idebenone-0.004
C: Idebenone0.085
D: Placebo0.024

[back to top]

Change in Peak Workload From Baseline to Week 52

"Assessed by a modified exercise test, in a subset of patients able to undertake this.~Wpeak has been calculated from the following formula: Workload last fully completed stage + (seconds completed in last stage / 60 * (4 [if arm ergonometry] or 10 [if leg ergonometry]))." (NCT00905268)
Timeframe: 1 year

InterventionWatts (Mean)
Group A: Idebenone1.15
Group B: Idebenone-7.41
C: Idebenone-6.91
D: Placebo-1.54

[back to top]

Proportion of Patients Improving (Responding) on ICARS by a Clinically Relevant Margin

"The International Cooperative Ataxia Rating Scale (ICARS) is a commonly used evaluation and is composed of four clinical sub-scores involving the following: posture and gait, limb coordination, speech and oculomotor function.The ICARS score is the total sum of the sub scores and ranges from 0 to 100, with 100 indicative of the most severely affected outcome.~ICARS Responder Analysis at Week 52: Percentage of subjects Improving by 2.5 Points or More." (NCT00905268)
Timeframe: week 52

Interventionpercentage of patients (Number)
Group A: Idebenone18.2
Group B: Idebenone23.6
C: Idebenone23.7
D: Placebo31

[back to top]

Proportion of Patients Improving on Left Ventricular Peak Systolic Strain Rate or Showing a Reduction in Left Ventricular Mass Index (LVMI) With no Worsening in Strain Rate

(In the statistical analysis sub-population presenting with cardiac involvement as defined by the FRDA cardiomyopathy criteria) (NCT00905268)
Timeframe: 1 year

Interventionpercentage of patients (Number)
Group A: Idebenone50
Group B: Idebenone51.4
C: Idebenone30.3
D: Placebo44.1

[back to top]

Absolute Change in Friedreich's Ataxia Rating Scale (FARS) Scores From Baseline Assessment to Week 52

The Friedreich Ataxia Rating Scale (FARS) is made up of a measure of ataxia, and activities of daily living subscale and a neurological subscale. The scores from the three subscales are added to generate a total score ranging from 0 to 159, with a higher score indicating a greater level of disability. (NCT00905268)
Timeframe: Baseline and week 52

Interventionunits on a scale (Mean)
Group A: Idebenone0.9
Group B: Idebenone1.2
C: Idebenone1.4
D: Placebo0.9

[back to top]

Absolute Change in International Cooperative Ataxia Rating Scale (ICARS) Scores From Baseline Assessment to Week 52

The International Cooperative Ataxia Rating Scale (ICARS) is a commonly used evaluation and is composed of four clinical sub-scores involving the following: posture and gait, limb coordination, speech and oculomotor function.The ICARS score is the total sum of the sub scores and ranges from 0 to 100, with 100 indicative of the most severely affected outcome. (NCT00905268)
Timeframe: Baseline and week 52

Interventionunits on a scale (Mean)
Group A: Idebenone1.6
Group B: Idebenone1.7
C: Idebenone1.2
D: Placebo1.1

[back to top]

Change in Slopes of 25FW Time From Baseline to Treatment Phase

"Lower extremity disability was measured by an average of two trials of timed 25 foot walk assessed at month -12, -6, and 0 for the baseline phase and at month 0, 6, 12, 18, and 24 for the treatment phase. The progression rate was calculated as a difference between baseline and treatment slopes using a piecewise linear mixed-effect model with breaking point at month 0.~The maximum time assigned for a trial is 180s. Patients unable to complete the 25 foot trial within this time limit are coded as 179.9" (NCT00950248)
Timeframe: 1-year pre-treatment baseline vs 2-year treatment period

Interventionseconds per year (Mean)
Idebenone0.02451
Placebo-0.01015

[back to top]

Change in Slopes of 9HPT Time From Baseline to Treatment Phase

"Upper extremity/fine motor movements disability was measured as an average of left and right hand time, with each hand assessed as an average of two trials with upper limit of 5 (300s) per trial. Patients unable to complete the task within this time are coded as 777 The outcome was assessed at month -12, -6, and 0 for the baseline phase and at month 0, 6, 12, 18, and 24 for the treatment phase. The progression rate was calculated as a difference between baseline and treatment slopes using a piecewise linear mixed-effect model with breaking point at month 0." (NCT00950248)
Timeframe: 1-year pre-treatment baseline vs 2-year treatment period

Interventionseconds per year (Mean)
Idebenone0.001693
Placebo-0.0003

[back to top]

Change in Slopes of EDSS From Baseline to Treatment Phase

EDSS scale combines various elements of neurological exam. EDSS is a discrete scale ranging from 0 to 10 with 0.5 point increments. EDSS of 0 means no neurological disability, while EDSS of 10 marks death due to MS. EDSS was assessed at month -12, -6, and 0 for the baseline phase and at month 0, 6, 12, 18, and 24 for the treatment phase.The progression rate was calculated as a difference between baseline and treatment slopes using a piecewise linear mixed-effect model with breaking point at month 0. (NCT00950248)
Timeframe: 1-year pre-treatment baseline vs 2-year treatment period

Interventionunits on a scale per year (Mean)
Idebenone1.6148
Placebo-3.7879

[back to top]

Change in the AUC of Individualized Rates of Enlargement of Ventricular Volume From Baseline to Treatment Phase

"The AUCs of the Ventricular volume scores (individualized rates of enlargement of segmented volume of lateral and 3rd ventricles) during the baseline and the 2-year treatment period were assessed using an ANCOVA model with the AUC of the pre-treatment Volumetric score, Baseline (Month 0) Volumetric score, and group as covariates.~The AUC values were calculated for both the pre-treatment baseline phase (from Months -12, -6, and 0) and for the double-blind phase (from Months 0, 6, 12, 18 and 24).~Because the follow-up times varied from patient to patient, the AUC values were made comparable by scaling them by dividing the AUC value by the square of the actual duration (in years) of each of the phases." (NCT00950248)
Timeframe: 1-year pre-treatment baseline vs 2-year treatment period

Interventionml per year (Mean)
Idebenone-244
Placebo35.4382

[back to top]

Change in the Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) From Baseline to Treatment Phase

"The AUCs of the CombiWISE scores during the 2-year treatment period was analyzed using an Analysis of Covariance (ANCOVA) model with the AUC of the pre-treatment CombiWISE scores, Baseline (Month 0) CombiWISE score and Baseline age as covariates.~CombiWISE is a composite scale derived from Expanded Disability Status Scale (EDSS) , Scripps Neurological Disability Scale (SNRS), times 25 foot walk (25FW), and non-dominant hand of 9 hole peg test (9HPT) with a minimum value of 0 (no disability) and maximum value of 100 (maximum disability).~The AUC values were calculated for both the pre-treatment baseline phase (from Months -12, -6, and 0) and for the double-blind phase (from Months 0, 6, 12, 18, and 24).~Because the follow-up times varied from patient to patient, the AUC values were made comparable by scaling them by dividing the AUC value by the square of the actual duration (in years) of each of the phases." (NCT00950248)
Timeframe: 1-year pre-treatment baseline vs 2-year treatment period

Interventionunits on a scale per year (Mean)
Idebenone-0.13
Placebo-1.04

[back to top]

Change in Slopes of SNRS From Baseline to Treatment Phase on

SNRS scale combines various elements of a neurological exam into a single number. The scale ranges from 100 to 0, where 100 marks no disability and 0 marks maximum disability. SNRS was assessed at month -12, -6, and 0 for the baseline phase and at month 0, 6, 12, 18, and 24 for the treatment phase. The progression rate was calculated as a difference between baseline and treatment slopes using a piecewise linear mixed-effect model with breaking point at month 0. (NCT00950248)
Timeframe: 1-year pre-treatment baseline vs 2-year treatment period

Interventionunits on a scale per year (Mean)
Idebenone1.5728
Placebo0.2315

[back to top]

Disability Progression Measured by EDSS-plus

"Categorical time-to-event endpoints (EDSS-plus) were analyzed using Cox Proportional hazards models, with treatment group as a covariate. The EDSS-plus event was defined as disability progression on at least 1 of 3 components [EDSS, 25FW, and/or non-dominant hand 9HPT]) confirmed 6 months apart and with a ≥ 20% minimum threshold change for 25FW and non-dominant hand 9HPT).~The patients who did not have an event during the study were censored at the time of the last assessment of EDSS-plus. The number of months from the date of first dose to date of event or censoring were used as endpoint. The measure is time to disease progression and unit of this measure is months." (NCT00950248)
Timeframe: 2-year treatment period

Interventionmonths (Median)
Idebenone23.1
Placebo23.7

[back to top]

Measures of Safety and Tolerability: Nature and Frequency of Adverse Events (AEs)

Global Overvbiew of accurance of AEs-Safety population. The Safety population included all subjects who received at least one dose of the study medication. (NCT00993967)
Timeframe: overall study, up to 24 months

Interventionparticipants (Number)
With at least one AEWith at least one drug-related AEWith at least one severe AEWith any significant AEDeathOther serious adverse events than deathAEs leading to discontinuation
Idebenone18810985414826

[back to top]

Absolute Change in The International Cooperative Ataxia Rating Scale (ICARS)

The International Cooperative Ataxia Rating Scale (ICARS) is a commonly used evaluation and is composed of four clinical sub-scores involving the following: posture and gait, limb coordination, speech and oculomotor function.The ICARS score is the total sum of the sub scores and ranges from 0 to 100, with 100 indicative of the most severely affected outcome. (NCT00993967)
Timeframe: Baseline, Month 12 and month 24

Interventionunits on a scale (Mean)
From Baseline to Month 12From Baseline to Month 24
Idebenone1.412.88

[back to top]

Change From Baseline to Week 52 in Muscle Strength

"The change from Baseline to Week 52 in muscle strength as measured by Hand-Held Myometry (HHM) was performed following standardized procedures. As almost all patients were non-ambulatory, only analyses of upper limb muscle strength were performed. Results for elbow flexors and for elbow extensors are reported below.The highest value of 3 consecutive measurements with an interval of at least 10 seconds were recorded.~The HHM was measured using MicroFET2, a digital hand held muscle tester. The selected unit of measure was Newtons (N)." (NCT01027884)
Timeframe: Baseline and Week 52

,
InterventionNewtons (Mean)
Elbow FlexorsElbow Extensors
Idebenone-2.320.26
Placebo0.131.32

[back to top]

Percentage of Patients Reporting Adverse Events

(NCT01027884)
Timeframe: 52 Weeks

Interventionpercentage of patients reporting AEs (Number)
Placebo94.1
Idebenone93.8

[back to top]

Change From Baseline to Week 52 in Quality of Life Assessed by PedsQL™ Paediatric Quality of Life Inventory

"PedsQL Quality of Life Inventory contains paediatric HRQOL measurements: Physical, Emotional,Social and School Functioning.~Item Scaling:~5-point Likert scale from 0 (Never) to 4 (Almost always). 3-point scale: 0 (Not at all), 2 (Sometimes) and 4 (A lot) for the Young Child (ages 5-7).~Scores are transformed on a scale from 0 to 100 ( 0=100, 1=75, 2=50, 3=25, 4=0) Total Score: Sum of all the items over the number of items answered on all the Scales.~The values reported below are overall scores on Paediatric Quality of Life Inventory in Child/Teen Report. These scores were obtained by averaging scores for all the described subscales. The overall scores range between 0-100 with 0 = worst outcome and 100= best outcome" (NCT01027884)
Timeframe: Baseline and Week 52

Interventionunits on a scale (Mean)
Placebo2.46
Idebenone-1.34

[back to top]

Change From Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Week 52

Change from Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Week 52 (NCT01027884)
Timeframe: Baseline and Week 52

Interventionpercentage (Geometric Mean)
Placebo-8.84
Idebenone-2.57

[back to top]

Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52

Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52 (NCT01027884)
Timeframe: Baseline and Week 52

Interventionpercentage of Predicted FVC (Mean)
Placebo-8.95
Idebenone-5.67

[back to top]

Comparison of the Percentage of Participants Randomised to Idebenone and Placebo Who Withdrew Early Due to Recurrence or Worsening of FRDA Symptoms

There was no Withdrawal due to recurrence or worsening of FRDA symptoms (NCT01303406)
Timeframe: Within 2 months (i.e. Early withdrawal visit)

Interventionpercentage of patients (Number)
Placebo0
Idebenone0

[back to top]

Patient Assessment of Treatment Assignment: Comparison of the Proportions of Patients Randomised to Idebenone and Placebo Who Assessed That They Received Idebenone

The primary efficacy endpoint was the comparison of the number of patients randomized to idebenone and placebo, who assessed that they received idebenone treatment. (NCT01303406)
Timeframe: At 2 months after study start

Interventionparticipants (Number)
Placebo6
Idebenone8

[back to top]

Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE)

"CombiWISE is a composite scale derived from Expanded Disability Status Scale (EDSS) , Scripps Neurological Disability Scale (SNRS), times 25 foot walk (25FW), and non-dominant hand of 9 hole peg test (9HPT) with a minimum value of 0 (no disability) and maximum value of 100 (maximum disability).~The AUC values were calculated for both study groups (Active treatment group in the 09-I-0197 trial and Placebo group in the 09-I-0197) as follows:~pre-treatment baseline during the 09-I-0197 trial (from Months -12, -6, and 0)~double-blind phase during the 09-I-0197 trial (from Months 0, 6, 12, 18, and 24)~extension phase during the 13-I-0088 trial (from Months 24, 30, and 36)~Because the follow-up times varied from patient to patient, the AUC values were made comparable by scaling them by dividing the AUC value by the square of the actual duration (in years) of each of the phases." (NCT01854359)
Timeframe: 1-year pre-treatment baseline vs 2-year randomized double-blind phased vs 1-year treatment period

Interventionunits on a scale * year (Mean)
Pre-treatment Baseline (Placebo Group)1.55
Double-blind Phase (Placebo Group)0.80
Extension Phase (Placebo Group)0.46
Pre-treatment Baseline (Active Treatment Group)0.89
Double-blind Phase (Active Treatment Group)0.75
Extension Phase (Active Treatment Group)1.30

[back to top]

Change in Slopes of Scripps Neurological Rating Scale (SNRS) Score

"Slopes of measured SNRS scores during the 3-year 09-I-0197 trial (one year of pre-treatment baseline and two years of double-blind randomized treatment) and during one year extension phase of the 13-I-0088 trial. The slopes were measured separately for placebo and active treatment arm as randomized in the the 09-I-0197 trial.~SNRS scale combines various elements of a neurological exam into a single number. The scale ranges from 100 to 0, where 100 marks no disability and 0 marks maximum disability.~SNRS was assessed every 6 months." (NCT01854359)
Timeframe: 3-years double-blind phase and 1-year extension phase

Interventionscore on a scale per year (Mean)
Placebo Arm of the 09-I-0197-1.8838
Extension Phase (Placebo Arm)-2.1655
Active Treatment Arm of the 09-I-0197-2.009
Extension Phase (Active Treatment Arm)-2.7263

[back to top]

Slopes of 25 Foot Walk (25FW) Time

"slopes of measured times of 25FW during the 3-year 09-I-0197 trial (one year of pre-treatment baseline and two years of double-blind randomized treatment) and during one year extension phase of the 13-I-0088 trial. The slopes were measured separately for placebo and active treatment arm as randomized in the the 09-I-0197 trial.~Lower extremity disability was measured by an average of two trials of timed 25 foot walk assessed every 6 month.~The maximum time assigned for a trial is 180s. Patients unable to complete the 25 foot trial within this time limit are coded as 179.9" (NCT01854359)
Timeframe: 3-years double-blind phase and 1-year extension phase

Interventionseconds per year (Mean)
Placebo Arm of the 09-I-01970.04322
Extension Phase (Placebo Arm)-0.00531
Active Treatment Arm of the 09-I-01970.04031
Extension Phase (Active Treatment Arm)0.03401

[back to top]

Slopes of 9 Hole Peg Test (9HPT) Time

"Slopes of measured times of 9HPT during the 3-year 09-I-0197 trial (one year of pre-treatment baseline and two years of double-blind randomized treatment) and during one year extension phase of the 13-I-0088 trial. The slopes were measured separately for placebo and active treatment arm as randomized in the the 09-I-0197 trial.~Upper extremity/fine motor movements disability was measured as an average of left and right hand time, with each hand assessed as an average of two trials with upper limit of 5 (300s) per trial. Patients unable to complete the task within this time are coded as 777 The outcome was assessed every 6 months." (NCT01854359)
Timeframe: 3-years double-blind phase and 1-year extension phase

Interventionseconds per year (Mean)
Placebo Arm of the 09-I-01970.000665
Extension Phase (Placebo Arm)0.000947
Active Treatment Arm of the 09-I-01970.000718
Extension Phase (Active Treatment Arm)0.001086

[back to top]

Slopes of Expanded Disability Status Scale (EDSS) Score

"Slopes of measured EDSS scores during the 3-year 09-I-0197 trial (one year of pre-treatment baseline and two years of double-blind randomized treatment) and during one year extension phase of the 13-I-0088 trial. The slopes were measured separately for placebo and active treatment arm as randomized in the the 09-I-0197 trial.~EDSS scale combines various elements of neurological exam. EDSS is a discrete scale ranging from 0 to 10 with 0.5 point increments. EDSS of 0 means no neurological disability, while EDSS of 10 marks death due to Multiple Sclerosis (MS). EDSS was assessed every 6 months." (NCT01854359)
Timeframe: 3-years double-blind phase and 1-year extension phase

Interventionscore on a scale per year (Mean)
Placebo Arm of the 09-I-01970.1447
Extension Phase (Placebo Arm)0.1435
Active Treatment Arm of the 09-I-01970.1107
Extension Phase (Active Treatment Arm)0.1584

[back to top]

Proportion (Number) of Eyes With Clinically Relevant Recovery of Visual Acuity From Baseline

Proportion (number) of eyes with clinically relevant recovery of visual acuity (VA) from Baseline or in which Baseline VA better than 1.0 logMAR was maintained at Month 12 in patients treated with Raxone® ≤1 year after the onset of symptoms, compared to matching external natural history control group (NCT02774005)
Timeframe: 12 months

Interventioneyes (Count of Units)
Raxone60

[back to top]

Components of the Primary Endpoint: Proportion of Eyes With Clinically Relevant Recovery (CRR) of VA From Baseline at Month 12 Compared to Matching External National History (NH) Control Group

"CRR is defined as:~Improvement from off-chart (the equivalent of Counting fingers, Hand motion, Light perception or No light perception) Visual Acuity to at least 1.6 logMAR value, OR~Improvement of at least 0.2 logMAR value within on-chart Visual Acuity A patient had a CRR if at least one eye had CRR.~logMAR = Logarithm of the minimum angle of resolution" (NCT02774005)
Timeframe: 12 months

Interventioneyes (Count of Units)
Raxone47

[back to top]

Components of the Primary Endpoint: Proportion of Eyes in Which Baseline Visual Acuity (VA) Better Than 1.0 logMAR Was Maintained at Month 12 (Clinically Relevant Stabilization) Compared to Matching External NH Control Group

"For proportion of eyes in which baseline VA better than 1.0 logMAR was maintained at Month 12 (CRS) compared to matching external NH control group only patients having VA < 1.0 at baseline are taking into account.~Clinically relevant stabilization (CRS) was defined as maintenance of VA <1.0 logMAR in eyes with VA <1.0 logMAR at Baseline.~A patient had a CRS if at least one eye had CRS.~logMAR = Logarithm of the minimum angle of resolution" (NCT02774005)
Timeframe: 12 months

Interventioneyes (Count of Units)
Raxone20

[back to top]